Novel peptide and composition for improving skin comprising same

Abstract

The present disclosure relates to a novel peptide and a composition for alleviating skin aging, a composition for caring for skin damage or alleviating skin sagging, a composition for reversing aging, an anti-glycation composition, a composition for preventing hair loss or promoting hair growth, and a composition for improving skin barrier function, wherein the compositions comprise the novel peptide.

Description

Novel peptide and skin improvement composition containing the same

[0001] [Cross-reference to related applications]

[0002] The present application is Korean Patent Application No. 10-2024-0146637 filed on October 24, 2024; Korean Patent Application No. 10-2024-0146679 filed on October 24, 2024; Korean Patent Application No. 10-2025-0095398 filed on July 15, 2025; Korean Patent Application No. 10-2025-0095399 filed on July 15, 2025; Korean Patent Application No. 10-2025-0097322 filed on July 18, 2025; Korean Patent Application No. 10-2025-0106050 filed on August 1, 2025; and 2025 Claiming priority to Korean Patent Application No. 10-2025-0155041 filed on October 23, 2025 and Korean Patent Application No. 10-2025-0155043 filed on October 23, 2025, the entire contents of these applications are incorporated by reference into this application.

[0003] The present disclosure relates to a novel peptide and a skin-improving composition containing the same.

[0004] The skin serves as the body's primary defense barrier, protecting internal organs from external environmental stimuli such as changes in temperature and humidity, ultraviolet rays, and pollutants, while also playing a crucial role in maintaining biological homeostasis, including thermoregulation. However, excessive physical and chemical stimuli, stress, and nutritional deficiencies from the outside can impair normal skin function and accelerate skin aging phenomena such as loss of elasticity, keratinization, and wrinkle formation. To prevent these phenomena and maintain healthier, more elastic skin, efforts have been made to effectively inhibit skin aging by using cosmetics fortified with bioactive substances derived from various plants and microorganisms, thereby preserving the skin's inherent functions and activating skin cells. However, most existing cosmetic ingredients have various problems, such as insufficient efficacy or causing skin side effects.

[0005] As the outermost organ exposed to the outside, the skin can be significantly affected by the external environment. External stimuli reduce the production and breakdown of collagen, leading to a decrease in its quantity. Among the collagens whose quantity decreases is the collagen constituting the dermoepidermal junction (DEJ), which connects the epidermis and dermis. Col7A1 and Col17A1 are the collagens that make up the DEJ, and a decrease in the amount of these collagens impairs the DEJ's function of firmly holding cells together, causing or exacerbating skin sagging.

[0006] Meanwhile, existing publicly available technology has only conducted research on the skin efficacy of rose extract, but there were no research results regarding specific components within the rose extract.

[0007] Cellular senescence refers to the process in which the characteristics and functions of cells gradually degenerate, ultimately leading to apoptosis or the cessation of proliferation. Normally proliferating cells reach a state of irreversible growth arrest after a certain number of divisions, where they can no longer divide; this is called replicative senescence. This is a natural aging phenomenon that occurs as cells reach the end of their lifespan.

[0008] In addition, metabolic aging occurs in non-dividing cells as intracellular metabolic activity continues, but generally, the former, dividing aging, is referred to as cellular aging. This cellular aging is deeply associated with the arrest of the cell cycle, and within the cell, the expression of proliferation inhibitory factors is activated, thereby limiting cell proliferation.

[0009] Meanwhile, since blocking apoptosis or prolonging proliferation to inhibit cellular senescence leads to side effects and an increased risk of cancer, a safer approach is being sought through PDK1 inhibition. It is reported that PDK1 inhibition can reverse cellular senescence in the skin and reduce senescence factors in in vitro, human skin models, and exploratory placebo-controlled intervention trials (Juewon Kim et al. "Kaempferol Tetrasaccharides Restore Skin Atrophy via PDK1 Inhibition in Human Skin Cells and Tissues: Bench and Clinical Studies." Biomedicine & Pharmacotherapy, vol. 150, 2022, p. 113-22.).

[0010] Recently, research has been actively focused on the potential for 'reverse aging,' which goes beyond simply delaying aging to reversing the state of already aged cells. However, most anti-aging cosmetic ingredients to date focus on preventing the aging of young cells, and reverse aging ingredients that act on aged cells themselves to induce rejuvenation are extremely limited.

[0011] The inventors of the present disclosure sought to discover materials with anti-aging efficacy in a more objective and quantitative manner by comprehensively analyzing multiple markers related to skin structure, hydration, differentiation, inflammation, and the cell cycle, rather than relying on a single indicator in the evaluation of skin aging.

[0012] Glycation is a process in which free amino groups of proteins, such as lysine or arginine, react with carbonyl groups of reducing sugars to form Schiff bases, which are initial glycation products. These compounds then undergo a series of complex reactions, including condensation, rearrangement, oxidation, cleavage, and cyclization, to form irreversible Advanced Glycation End Products (AGEs). Recently, these AGEs have been referred to as glycotoxins and are attracting attention as causative agents of various tissue damages in the body.

[0013] Glycation reactions are a major issue in skin tissues as well; in particular, when glycation occurs in connective tissues within the dermis, fibrous tissues become hard and stiff, which can lead to structural and functional problems such as reduced flexibility and changes in skin tone. Accordingly, approaches to block or delay the formation of AGEs by inhibiting skin glycation have become an important strategy in the development of cosmetics and functional materials.

[0014] The inventor of the present disclosure sought to develop an anti-glycation functional composition that can effectively inhibit the formation of glycotoxins, namely AGEs, which are glycation products, and thereby improve stiffness, skin roughness, and skin color changes induced by glycation reactions in skin tissue.

[0015] Male pattern baldness is a phenomenon caused by the male hormone testosterone. When this testosterone is converted into a more potent hormone called dihydrotestosterone (DHT) by an enzyme called 5-alpha-reductase (α-reductase), this hormone acts on hair follicles to induce them from the growth phase to the regression phase, thereby causing hair loss. Therefore, methods that inhibit the production of DHT by 5-alpha-reductase are primarily used to treat male pattern baldness.

[0016] Female pattern hair loss is primarily caused by a decrease in estrogen levels after menopause. Minoxidil or estrogen is mainly used as a treatment for female pattern hair loss.

[0017] Alopecia areata is caused by autoimmune diseases, psychological stress, or genetic predisposition. Its causes are fundamentally different from androgenetic alopecia, and the treatments also differ; therefore, methods such as administering corticosteroids, applying minoxidil to the affected area, or artificially stimulating the skin are used.

[0018] Regarding the diverse and complex causes of hair loss, products containing ingredients aimed at promoting blood circulation, inhibiting male hormone activity, and strengthening hair root function are available on the market; however, none have yet demonstrated distinct efficacy, and concerns regarding side effects have been raised. For instance, Minoxidil has been reported to cause side effects such as a sticky sensation and skin irritation. In the case of Finasteride, although it is currently used as an oral formulation, not only have side effects such as sexual dysfunction been reported, but there are also significant inconveniences in use as it is only effective when administered orally.

[0019] Accordingly, there is a need to develop a cosmetic composition that prevents hair loss and promotes hair growth without side effects by deriving an optimal combination effective in inhibiting external root sheath cell apoptosis and utilizing it as an active ingredient.

[0020] The skin is a barrier organ located at the outermost layer of the human body and is continuously affected by various external environmental factors, such as sunlight, as well as internal factors like mental stress, hormonal changes, and nutritional status. The sum of these external and internal stimuli is generally referred to as the 'exposome,' and recently, it has been attracting attention as an important concept not only in health and disease research but also in the field of dermatology.

[0021] In particular, numerous reports have been made regarding the effects of exosome factors on the skin, such as mental stress and blue light, and it is known that these factors can inhibit the differentiation of keratinocytes and cause abnormalities in skin barrier function.

[0022] Meanwhile, there have been no reports yet on the effects of specific active ingredients, such as rose-derived peptides, on skin barriers damaged by exosomes.

[0023]

[0024] In one aspect, the present disclosure provides a peptide comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5.

[0025] In another aspect, the present disclosure provides a rose-derived extract comprising the above peptide.

[0026] In another aspect, the present disclosure provides a composition for skin improvement comprising a rose-derived peptide, wherein the skin improvement is one or more of the following: improvement of skin aging, antioxidant, care for skin damage, improvement of skin sagging, anti-aging of skin, anti-glycation, improvement of skin tone, prevention of hair loss or promotion of hair growth, strengthening of hair roots, promotion of eyelash growth, or improvement of skin barrier function damaged by exosomes.

[0027] In another aspect, the present disclosure provides a method for preparing the peptide or the composition, comprising the steps of: preparing a rose (Rosa damascena) extract; precipitating a rose-derived protein from the rose extract; treating the rose-derived protein with a protease to hydrolyze it; and inactivating the protease.

[0028] In another aspect, the present disclosure provides a rose-derived peptide prepared by the above method as the peptide.

[0029] In another aspect, the present disclosure provides a composition prepared by a method comprising the following steps as the composition: preparing a rose (Rosa damascena) extract; precipitating a rose-derived protein from the rose extract; treating the rose-derived protein with a protease to hydrolyze it; and inactivating the protease.

[0030]

[0031] In one aspect, the present disclosure provides a peptide comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5.

[0032] In an exemplary aspect, (a) the peptide is a peptide derived from rose flowers and / or; (b) the peptide is derived from a water extract of roses and / or; (c) the peptide is composed of one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5 and / or; (d) the peptide is a peptide obtained by adding a plant-derived enzyme to a rose-derived protein and / or; (e) the peptide is a peptide obtained by adding cysteine ​​protease to a rose-derived protein and / or; or (f) the peptide is a peptide obtained by adding bromelain to a rose-derived protein.

[0033] In another aspect, the present disclosure provides a rose-derived extract comprising the above peptide.

[0034] In another aspect, the present disclosure provides a composition for skin improvement comprising a rose-derived peptide, wherein the skin improvement is one or more of the following: improvement of skin aging, antioxidant, care for skin damage, improvement of skin sagging, anti-aging of skin, anti-glycation, improvement of skin tone, prevention of hair loss or promotion of hair growth, strengthening of hair roots, promotion of eyelash growth, or improvement of skin barrier function damaged by exosomes.

[0035] In an exemplary aspect, the skin aging improvement may be improving skin wrinkles, skin elasticity, or skin keratinization, the skin aging improvement may be inhibiting the secretion of neurotransmitters, and / or the skin aging improvement may be inhibiting the expression of collagen-degrading enzymes.

[0036] In an exemplary aspect, the neuronal substance is noradrenaline, and / or the collagen-degrading enzyme may be MMP-1 (Matrix metalloproteinase-1; Collagenase-1).

[0037] In an exemplary aspect, the composition may be applied to dermal fibroblasts and / or keratinocytes.

[0038] In an exemplary aspect, the improvement of skin damage or improvement of skin sagging may restore damage to the dermoepidermal junction, and / or the improvement of skin damage or improvement of skin sagging may increase the expression of collagen in the skin.

[0039] In an exemplary aspect, the collagen may be collagen type Col7A1 or Col17A1.

[0040] In an exemplary aspect, the skin damage mentioned above may be skin damage caused by fine dust.

[0041] In an exemplary aspect, the above anti-aging may include one or more selected from the group consisting of increased skin moisturizing ability, strengthening of the epidermal barrier, improvement of cell division ability, normalization of epidermal differentiation, increased skin regeneration ability, improvement of keratin shedding regulation, strengthening of intercellular adhesion, and inhibition of substrate-degrading enzyme activity.

[0042] In an exemplary aspect, the above anti-aging can improve one or more phenomena selected from the group consisting of a decrease in basal layer cell density of the skin induced by aging, indistinctness of intercellular boundaries, absence of keratohyalin granules and persistence of nuclei within the stratum corneum.

[0043] In an exemplary aspect, the anti-aging increases the mRNA expression level of one or more selected from the group consisting of Col17a (Collagen type XVII alpha 1 chain), FLG (Filaggrin), KLK5 (Kallikrein-related peptidase 5), KRT10 (Keratin 10), SOX2 (SRY-Box Transcription Factor 2), and CLDN1 (Claudin-1), and / or

[0044] It can reduce the mRNA expression levels of p16 (Cyclin-dependent kinase inhibitor 2A) and / or MMP-2 (Matrix Metallopeptidase 2).

[0045] In an exemplary aspect, the above anti-glycation or skin tone improvement can inhibit the formation of Advanced Glycation End products.

[0046] In an exemplary aspect, the skin tone improvement mentioned above may be an improvement in the yellow tone or yellowing of the skin.

[0047] In an exemplary aspect, the skin improvement is anti-glycation or skin tone improvement, and the rose-derived peptide can be treated to cells at a concentration of 0.25 to 10,000 ppm (w / v).

[0048] In an exemplary aspect, the skin improvement is to prevent hair loss or promote hair growth; strengthen hair roots; or promote eyelash growth, and the composition may further include acetyl dipeptide-1 cetyl ester.

[0049] In an exemplary aspect, the composition may include the rose-derived peptide and the acetyl dipeptide-1-cetyl ester in a weight ratio of 1 to 100:1.

[0050] In an exemplary aspect, the composition comprises 0.00001 to 0.1 weight% of the rose-derived peptide, and / or

[0051] The above acetyl dipeptide-1-cetyl ester may be included in an amount of 0.000001 to 0.01 weight%.

[0052] In an exemplary aspect, the rose-derived peptide may be treated to cells at a concentration of 0.1 to 1000 ppm (w / v), and / or the acetyldipeptide-1-cetyl ester may be treated to cells at a concentration of 0.01 to 100 ppm (w / v).

[0053] In an exemplary aspect, the above-mentioned prevention of hair loss or promotion of hair growth; strengthening of hair roots; or promotion of eyelash growth may proliferate hair papilla cells and / or inhibit the death of outer root sheath cells.

[0054] In an exemplary aspect, the exosome may be mental stress and / or blue light.

[0055] In an exemplary aspect, the mental stress mentioned above may be stress caused by glucocorticoid hormones.

[0056] In an exemplary aspect, the glucocorticoid hormone may be one or more selected from cortisol, cortisone, and corticosterone.

[0057] In an exemplary aspect, the wavelength of the blue light may be 380 to 500 nm.

[0058] In an exemplary aspect, the improvement of damaged skin barrier function by the exosome may be one or more selected from the group consisting of promoting differentiation of keratinocytes, promoting intercellular binding of keratinocytes, and improving skin hydration.

[0059] In an exemplary aspect, the improvement of damaged skin barrier function by the exosome may promote the expression of one or more mRNAs selected from the group consisting of KRT1 (Keratin 1), KRT10 (Keratin 10), FLG (Filaggrin), LOR (Loricrin), CASP14 (Caspase 14), CLDN1 (Claudin 1) and TJP1 (Tight Junction Protein 1).

[0060] In an exemplary aspect, the above composition may be applied to the epidermal layer of the skin.

[0061] In an exemplary aspect, the skin improvement mentioned above is the improvement of damaged skin barrier function by exosome, and

[0062] The above rose-derived peptide can be treated to cells at a concentration of 0.1 to 100 ppm (w / v).

[0063] In an exemplary aspect, the rose-derived peptide may be a rose flower-derived peptide.

[0064] In an exemplary aspect, the rose-derived peptide may be derived from a rose water extract.

[0065] In an exemplary aspect, the rose-derived peptide may comprise one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5.

[0066] In an exemplary aspect, the rose-derived peptide may be a peptide obtained by adding a plant-derived enzyme to a rose-derived protein.

[0067] In an exemplary aspect, the rose-derived peptide may be a peptide obtained by adding cysteine ​​protease to a rose-derived protein.

[0068] In another aspect, the present disclosure may provide a method for preparing the peptide or the composition, comprising the steps of: preparing a rose (Rosa damascena) extract; precipitating a rose-derived protein from the rose extract; treating the rose-derived protein with a protease to hydrolyze it; and inactivating the protease.

[0069] In an exemplary aspect, the preparation of the rose (Rosa damascena) extract may be carried out by hot water extraction of rose flowers, or the precipitation of the rose-derived protein may be carried out by adjusting the pH of the rose extract to 8 or higher to induce elution, and then adjusting the pH to 5 or lower.

[0070] In an exemplary aspect, the method may further include a step of neutralizing the protein by adjusting the pH of the rose extract to 6 to 8 after the step of precipitating the protein and before the step of hydrolyzing the protein.

[0071] In another aspect, the present disclosure may provide a rose-derived peptide prepared by the above method as the peptide.

[0072] In another aspect, the present disclosure may provide a composition prepared by a method comprising the following steps as the composition: preparing a rose (Rosa damascena) extract; precipitating a rose-derived protein from the rose extract; hydrolyzing the rose-derived protein by treating it with a protease; and inactivating the protease.

[0073]

[0074] In one aspect, the novel peptide of the present disclosure and the composition containing it have excellent skin aging improvement and antioxidant effects.

[0075] In one aspect, the novel peptide of the present disclosure and the composition containing it have excellent effects in improving skin wrinkles, skin elasticity, or skin keratinization.

[0076] In one aspect, the novel peptide of the present disclosure and the composition containing it have excellent effects of inhibiting the secretion of noradrenaline, a neurotransmitter of nerve cells, and inhibiting the activity of MMP-1 (Matrix metalloproteinase-1; Collagenase-1), a collagen-degrading enzyme.

[0077] In one aspect, the novel peptide or rose-derived peptide of the present disclosure can be extracted from natural products, so it has no adverse effects on the skin compared to synthetic compounds.

[0078] In one aspect, the composition of the present disclosure has excellent effects in caring for skin damage caused by fine dust and improving skin sagging.

[0079] In one aspect, the composition of the present disclosure has an excellent effect of restoring damage to the dermoepidermal junction and can restore the expression of collagen types Col7A1 and Col17A1 in skin cells that have been reduced.

[0080] In one aspect, the rose-derived peptide of the present disclosure has an excellent anti-aging effect that restores reduced gene expression in aged keratinocytes to the level of young cells.

[0081] In one aspect, the rose-derived peptide of the present disclosure has excellent effects in restoring skin youthfulness by restoring the expression of genes key to skin structure and function, including Col17a, FLG, KLK5, KRT10, SOX2, and CLDN1, and reducing the expression of genes such as p16 and MMP-2, and can induce anti-aging of skin tissue by improving structural degeneration and differentiation abnormalities appearing in artificial epidermis composed of aged keratinocytes and restoring normal epidermal layer structure and function, and has great potential for use as an anti-aging-based cosmetic material that induces structural and functional reversal of the skin.

[0082] In one aspect, the rose-derived peptide of the present disclosure has an excellent skin glycation inhibitory effect.

[0083] In one aspect, the rose-derived peptide of the present disclosure has an excellent effect of inhibiting the formation of Advanced Glycation End Products in the skin and an excellent effect of improving skin tone, including yellowness and dullness.

[0084] In one aspect, the composition of the present disclosure has an excellent effect on the proliferation of dermal papilla cells and an excellent effect on inhibiting the death of outer root sheath cells.

[0085] In one aspect, the composition of the present disclosure has excellent effects in preventing hair loss, promoting hair growth, strengthening hair roots, and promoting eyelash growth.

[0086] In one aspect, the combination of the rose-derived peptide and Acetyl Dipeptide-1 Cetyl ester of the present disclosure exhibits a synergistic effect when used in combination.

[0087] In one aspect, the rose-derived peptide of the present disclosure has an excellent effect in improving skin barrier function damage caused by the Exposome factor.

[0088] In one aspect, the rose-derived peptide of the present disclosure has the effect of significantly restoring the expression of keratinocyte differentiation markers (KRT1, KRT10, FLG, LOR) that are inhibited by the stress hormone (cortisol), and contributes to skin protection and barrier strengthening by improving the expression of moisturization-related genes (CASP14, FLG) and intercellular binding proteins (CLDN, TJP1) that are reduced by blue light, and can help protect the skin from external stress and maintain a healthy skin condition by complexly regulating differentiation, moisturization, and binding-related genes, which are major functional indicators of the skin barrier.

[0089]

[0090] Figure 1 is the result of an experiment confirming the antioxidant effect of a rose-derived peptide according to one embodiment of the present disclosure.

[0091] Figure 2 is the result of an experiment confirming the antioxidant effect according to the concentration of a rose-derived peptide according to one embodiment of the present disclosure.

[0092] FIG. 3 is the result of an experiment on the neurotransmitter secretion inhibitory efficacy of a rose-derived peptide using botulinum toxin Type A as a positive control according to one embodiment of the present disclosure.

[0093] Figure 4 is the result of an experiment on the neurotransmitter secretion inhibitory efficacy of a rose-derived peptide according to one embodiment of the present disclosure.

[0094] Figure 5 is the result of a cytotoxicity confirmation experiment of a rose-derived peptide according to one embodiment of the present disclosure.

[0095] Figure 6 is the result of an experiment on the inhibition of collagenase (MMP 1) activity by a rose-derived peptide according to one embodiment of the present disclosure.

[0096] Figure 7 is the result of a cytotoxicity experiment using a rose-derived peptide according to one embodiment of the present disclosure.

[0097] Figure 8 is the result of an experiment on the recovery of Col7A1 expression levels by a rose-derived peptide according to one embodiment of the present disclosure.

[0098] Figure 9 is the result of an experiment on the recovery of Col17A1 expression levels by a rose-derived peptide according to one embodiment of the present disclosure.

[0099] FIG. 10 shows the experimental results of changes in aging markers in young keratinocytes (passage 3) and aged keratinocytes (passage 6) according to one embodiment of the present disclosure.

[0100] Figure 11 shows experimental results comparing changes in aging marker expression when aged keratinocytes (passage 6) according to one embodiment of the present disclosure are treated with a rose-derived peptide (rose peptide, 10 ppm).

[0101] FIG. 12 shows the results of a comparative experiment on artificial epidermal morphology when neonatal keratinocytes according to one embodiment of the present disclosure are aging by passage 9 and then treated with a rose-derived peptide.

[0102] FIG. 13 shows the experimental results analyzing the effect of a rose-derived peptide according to one embodiment of the present disclosure on the epidermal growth of newly formed keratinocytes and adult keratinocytes aged 45.

[0103] Figure 14 is the result of a comparative experiment on the inhibition of AGEs formation by glucose using a rose-derived peptide and a rose hot water extract according to one embodiment of the present disclosure.

[0104] Figure 15 is the result of a comparative experiment on the inhibition of AGEs formation by glucose using a rose-derived peptide in cells according to one embodiment of the present disclosure.

[0105] Figure 16 is the result of an experiment evaluating the proliferation of dermal papilla cells with a rose-derived peptide and Acetyl Dipeptide-1 Cetyl ester according to one embodiment of the present disclosure.

[0106] FIG. 17 is the result of an experiment evaluating the inhibition of apoptosis in outer root sheath cells by a rose-derived peptide and Acetyl Dipeptide-1 Cetyl ester according to one embodiment of the present disclosure.

[0107] FIG. 18 is an experimental result confirming the efficacy of a rose-derived peptide according to one embodiment of the present disclosure in inhibiting the expression of differentiation markers in keratinocytes (NHEK-neo) by the stress hormone (cortisol).

[0108] FIG. 19 is an experimental result confirming the efficacy of a rose-derived peptide according to one embodiment of the present disclosure in inhibiting the expression of differentiation markers, moisturization markers, and intercellular binding markers in keratinocytes (NHEK-neo) by blue light.

[0109] FIG. 20 is the experimental result comparing the efficacy of a rose-derived peptide according to one embodiment of the present disclosure in inhibiting the expression of the differentiation marker KRT1 in keratinocytes (HEKn) by the stress hormone (cortisol) with that of a rose hot water extract.

[0110] FIG. 21 is the experimental result comparing the efficacy of a rose-derived peptide according to one embodiment of the present disclosure in inhibiting the expression of the differentiation marker FLG in keratinocytes (HEKn) by the stress hormone (cortisol) with that of a rose hot water extract.

[0111] FIG. 22 is an experimental result confirming the efficacy of a rose-derived peptide according to one embodiment of the present disclosure in inhibiting the expression of keratin differentiation markers in artificial skin by a stress hormone (cortisol).

[0112]

[0113] The present disclosure will be described in detail below.

[0114]

[0115] In one aspect, the present disclosure provides a peptide comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5. For example, the peptide may consist of one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5, but is not limited thereto.

[0116] In an exemplary aspect, (a) the peptide is a peptide derived from rose flowers and / or; (b) the peptide is derived from a water extract of roses and / or; (c) the peptide is composed of one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5 and / or; (d) the peptide is a peptide obtained by adding a plant-derived enzyme to a rose-derived protein and / or; (e) the peptide is a peptide obtained by adding cysteine ​​protease to a rose-derived protein and / or; or (f) the peptide is a peptide obtained by adding bromelain to a rose-derived protein.

[0117] In another aspect, the present disclosure provides a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 5.

[0118] In another aspect, the present disclosure provides a rose-derived peptide comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5. For example, the rose-derived peptide may consist of one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5, but is not limited thereto.

[0119] In another aspect, the present disclosure provides a rose-derived extract comprising the above peptide.

[0120] While discovering antioxidant and anti-aging materials derived from rose extract, the inventors discovered novel peptides of SEQ ID NOs 1 to 5 derived from rose that have excellent antioxidant efficacy, neurotransmitter secretion inhibition efficacy, and collagenase activity inhibition efficacy.

[0121] In an exemplary embodiment, the amino acid sequence of SEQ ID NO. 1 is SSANGPLGGGAGM, the amino acid sequence of SEQ ID NO. 2 is RGMSPGGGGGGGL, the amino acid sequence of SEQ ID NO. 3 is STGANLAAASNP, the amino acid sequence of SEQ ID NO. 4 is STENLGGGGVAN, and the amino acid sequence of SEQ ID NO. 5 is TSNGALGGVSPN.

[0122] The above term "Rosa" refers collectively to plants belonging to the dicotyledonous group, Rosales, Rosaceae, and Rosa genus, and includes both wild species and improved horticultural varieties. Roses are shrubby flowering plants that are widely cultivated for ornamental and fragrance purposes due to their beautiful flowers and scents. It is stated that rose flowers have a sweet taste, a warm nature, are non-toxic, and possess the efficacy of promoting blood circulation and reducing swelling. For example, the above rose may be the Damask rose (Rosa damascena), but is not limited thereto.

[0123] In an exemplary embodiment, the rose-derived peptide refers to a peptide derived from the rose.

[0124] In an exemplary embodiment, the rose-derived peptide may be a rose flower-derived peptide. For example, the rose flower may include rose petals, rose pistils, rose stamens, rose ovules, or rose sepals, but is not limited thereto.

[0125] In an exemplary embodiment, the rose-derived peptide may be derived from a rose water extract.

[0126] In an exemplary embodiment, the extract may be obtained by extracting, separating, and fractionating from nature using methods of extraction, separation, and fractionation known in the art, and may be extracted according to various extraction or fractionation solvents and extraction methods.

[0127] In an exemplary embodiment, the extraction method of the extract may include hot water extraction, cold maceration extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and pressing, but is not limited thereto.

[0128] In an exemplary embodiment, the average molecular weight of the rose-derived peptide may be 3000 Da or less. For example, the average molecular weight of the rose-derived peptide may be 3000 Da or less, 2800 Da or less, 2600 Da or less, 2400 Da or less, 2000 Da or less, 1900 Da or less, 1800 Da or less, 1700 Da or less, 1600 Da or less, 1500 Da or less, 1400 Da or less, 1300 Da or less, 1200 Da or less, 1100 Da or less, or 1000 Da or less.

[0129] In another aspect, the present disclosure provides a composition for skin improvement comprising a rose-derived peptide, wherein the skin improvement comprises one or more of the following: improvement of skin aging, antioxidant, care for skin damage, improvement of skin sagging, anti-aging of the skin, anti-glycation, improvement of skin tone, prevention of hair loss or promotion of hair growth, strengthening of hair roots, promotion of eyelash growth, or improvement of skin barrier function damaged by exosomes. The composition may include therapeutic or non-therapeutic uses. Additionally, the composition may be an oral composition.

[0130] In an exemplary embodiment, for non-therapeutic use of the composition for skin improvement, the skin improvement may provide one or more of the following uses: improvement of skin aging, antioxidant, care for skin damage, improvement of skin sagging, anti-aging of the skin, anti-glycation, improvement of skin tone, prevention of hair loss or promotion of hair growth, strengthening of hair roots or promotion of eyelash growth, and improvement of damaged skin barrier function by exosome.

[0131] In an exemplary embodiment, the therapeutic use of the composition for skin improvement may provide a use in which the skin improvement is the improvement of damaged skin barrier function by the exosome.

[0132] In this specification, the term “skin” is a broad concept including the scalp or hair. Additionally, “skin improvement” is a concept that includes not only the improvement of general skin conditions but also improvements related to scalp and hair health. Accordingly, examples of skin improvement include hair shine, thickness, density, and improvement of the scalp environment.

[0133] In addition, the present disclosure provides a method for improving skin, comprising the step of administering a composition containing an effective amount of rose-derived peptide to a subject requiring skin improvement, wherein the skin improvement is one or more of the following: improvement of skin aging, antioxidant, care for skin damage, improvement of skin sagging, anti-aging of the skin, anti-glycation, improvement of skin tone, prevention of hair loss or promotion of hair growth, strengthening of hair roots, promotion of eyelash growth, or improvement of skin barrier function damaged by exosomes.

[0134] In another aspect, the present disclosure provides a composition for improving skin aging comprising a rose-derived peptide. The rose and the rose-derived peptide are as described above. Additionally, the present disclosure provides a use of the rose-derived peptide for the preparation of a composition for improving skin aging.

[0135] In an exemplary embodiment, the rose-derived peptide may comprise one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5. SEQ ID NOs 1 to 5 are as described above.

[0136] In an exemplary embodiment, the skin aging improvement may be to improve skin wrinkles, skin elasticity, or skin keratinization.

[0137] In an exemplary embodiment, the skin aging improvement may be achieved by inhibiting the secretion of neurotransmitters.

[0138] In an exemplary embodiment, the neuronal substance may be noradrenaline.

[0139] In an exemplary embodiment, the skin aging improvement may be achieved by inhibiting the expression of collagen-degrading enzymes.

[0140] In another aspect, the present disclosure provides an antioxidant composition comprising a rose-derived peptide. The rose and the rose-derived peptide are as described above. Additionally, the present disclosure provides a use of the rose-derived peptide for the preparation of an antioxidant composition.

[0141] In an exemplary embodiment, the collagenase may be MMP-1 (Matrix metalloproteinase-1; Collagenase-1).

[0142] In an exemplary embodiment, the composition may be applied to dermal fibroblasts.

[0143] In an exemplary embodiment, the rose-derived peptide may be treated to cells at a concentration of 0.1 to 1000 ppm (w / v). For example, the rose-derived peptide may be at a concentration of 0.1 ppm (w / v) or more, 0.5 ppm (w / v) or more, 1 ppm (w / v) or more, 1.5 ppm (w / v) or more, 2 ppm (w / v) or more, 2.5 ppm (w / v) or more, 3 ppm (w / v) or more, 3.5 ppm (w / v) or more, 4 ppm (w / v) or more, 4.5 ppm (w / v) or more, 5 ppm (w / v) or more, 5.5 ppm(w / v) or more, 6 ppm(w / v) or more, 10 ppm(w / v) or more, 20 ppm(w / v) or more, 30 ppm(w / v) or more, 40 ppm(w / v) or more, 50 ppm(w / v) or more, 60 ppm(w / v) or more, 70 ppm(w / v) or more, 80 ppm(w / v) or more, 90 ppm(w / v) or more, 100 ppm(w / v) or more, 120 ppm(w / v) or more, 140 ppm(w / v) or more, 160 ppm(w / v) or more, 180 ppm(w / v) or more, 200 ppm(w / v) or more, 300 ppm(w / v) or more, 400 ppm(w / v) or more, 500 ppm(w / v) It may be treated to cells at a concentration of 600 ppm (w / v) or more, 700 ppm (w / v) or more, 800 ppm (w / v) or more, 900 ppm (w / v) or more, or 1000 ppm (w / v) or more, and 1000 ppm (w / v) or less, 900 ppm (w / v) or less, 800 ppm (w / v) or less, 700 ppm (w / v) or less, 600 ppm (w / v) or less, 500 ppm (w / v) or less, 400 ppm (w / v) or less, 300 ppm (w / v) or less, 200 ppm (w / v) or less, 180 ppm (w / v) or less, 160 ppm (w / v) or less, 140 ppm (w / v) or less, 120 ppm (w / v) Cells may be treated at concentrations of 100 ppm (w / v) or less, 90 ppm (w / v) or less, 80 ppm (w / v) or less, 70 ppm (w / v) or less, 60 ppm (w / v) or less, 50 ppm (w / v) or less, 0 ppm (w / v) or less, 30 ppm (w / v) or less, 20 ppm (w / v) or less, 10 ppm (w / v) or less, 9 ppm (w / v) or less, 8 ppm (w / v) or less, 7 ppm (w / v) or less, 6 ppm (w / v) or less, 5 ppm (w / v) or less, 4 ppm (w / v) or less, or 3 ppm (w / v) or less.

[0144] In an exemplary embodiment, the composition may be for cosmetic use.

[0145] In an exemplary embodiment, the cosmetic composition may contain, in addition to the above ingredients, other ingredients capable of providing useful effects distinct from the main effect, to the extent that the main effect is not impaired. In addition to the active ingredients of the present disclosure, other ingredients may be appropriately selected and incorporated by a person skilled in the art according to the formulation or intended use of other cosmetic compositions without difficulty. Furthermore, as an example, the cosmetic composition of the present disclosure may include, in addition to the above ingredients, other ingredients conventionally incorporated into cosmetic compositions as needed. Examples include moisturizers, emollients, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, etc. Other ingredients that may be included in the cosmetic composition of the present disclosure are not limited thereto, and the amount of said ingredients may be within a range that does not impair the purpose and effect of the present disclosure.

[0146] In an exemplary embodiment, the cosmetic composition may be one or more formulations selected from the group consisting of massage creams, oils, body products, packs, masks, eye area products, lotions, creams, and makeup cosmetics, but is not limited thereto. Additionally, the composition of each of these formulations may contain additives that are necessary and appropriate for the formulation of the formulation.

[0147] In an exemplary embodiment, the composition may be for food use. For example, the food composition may be for antioxidant, anti-blemish improvement, maintenance of healthy blood sugar levels, or improvement of skin moisture status, but is not limited thereto.

[0148] In an exemplary embodiment, the food composition may include a food-grade additive that is food-gradely acceptable and may further include a suitable carrier, excipient, and diluent commonly used in the manufacture of food. The formulation of the food composition is not particularly limited, but may be formulated, for example, into tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc. For each formulation of the food composition, in addition to the active ingredient, ingredients commonly used in the field can be appropriately selected and combined by a person skilled in the art according to the formulation or purpose of use without difficulty, and a synergistic effect may occur when applied simultaneously with other raw materials.

[0149] In an exemplary embodiment, the food composition may include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and promoters (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Additionally, the food compositions according to one embodiment may include fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, they are generally included in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to one embodiment.

[0150] In an exemplary embodiment, the composition may be a pharmaceutical composition for the prevention or treatment of skin diseases caused by skin aging. The skin diseases caused by skin aging may be due to wrinkles, loss of elasticity, or keratinization, but are not limited thereto.

[0151] In an exemplary embodiment, the pharmaceutical composition may further contain pharmaceutical adjuvants such as preservatives, stabilizers, hydrating agents or emulsification promoters, salts and / or buffers for osmotic pressure regulation, and other therapeutically useful substances, and may be formulated into various oral or parenteral administration forms according to conventional methods.

[0152] In an exemplary embodiment, the oral dosage form may be, for example, a tablet, pill, hard and soft capsule, liquid, suspension, emulsifier, syrup, powder, granule, granule, pellet, etc., and these formulations may contain, in addition to the active ingredient, a surfactant, a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine), and a lubricant (e.g., silica, talc, stearic acid and its magnesium or calcium salt, and polyethylene glycol). The tablet may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidine, and, in some cases, may contain pharmaceutical additives such as disintegrants, absorbents, coloring agents, flavoring agents, and sweeteners, such as starch, agar, alginic acid, or its sodium salt. The tablet may be manufactured by conventional mixing, granulation, or coating methods. Additionally, the parenteral agent may be in the form of a rectal, topical, subcutaneous, or transdermal administration, and may be in the form of, for example, an injection, drops, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc., but is not limited thereto. A pharmaceutical composition according to one embodiment of the present specification may be administered topically, for example, to the scalp.

[0153] In an exemplary embodiment, the determination of the dosage of the active ingredient is within the level of a person skilled in the art, and the daily dosage of the drug varies depending on various factors such as the degree of symptom progression, onset time, age, health condition, and complications of the subject to administration, but generally, based on adults, the composition may be administered in divided doses of 1 μg / kg to 200 mg / kg, preferably 50 μg / kg to 50 mg / kg, 1 to 3 times a day, and the dosage does not limit the scope of this specification in any way.

[0154]

[0155] In another aspect, the present disclosure provides a composition for skin damage care comprising a rose-derived peptide. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of a rose-derived peptide for the preparation of a composition for skin damage care.

[0156] In the present disclosure, it was confirmed that the expression of Col7A1 and Col17A1, collagen types known to be important for skin DEJ function, was reduced in skin cells exposed to fine dust, which is one of the external irritants. In addition, it was confirmed that rose-derived peptides can restore DEJ function by increasing the expression of Col7A1 and Col17A1, which were reduced by fine dust in skin keratinocytes, thereby strengthening the connection between the dermis and epidermis and increasing skin stability.

[0157] In an exemplary embodiment, the skin damage may be skin damage caused by fine dust.

[0158] The above fine dust refers to particulate matter that is invisible to the human eye and floats or scatters in the atmosphere for a long time, with an average particle size of 10 μm or less. In particular, particulate matter with an average particle size of 2.5 μm or less is referred to as "ultrafine dust," and in this specification, "fine dust" is intended to include "ultrafine dust." The average particle size of the above fine dust refers to the volume average particle size obtained by calculating a specific average based on the particle size distribution measured by known particle size distribution measurement methods, such as electron microscope image observation or laser diffraction.

[0159] In an exemplary embodiment, the particle size of the fine dust may be 0.1 μm to 50 μm. For example, the particle size of the fine dust may be 0.1 μm or more, 0.2 μm or more, 0.3 μm or more, 0.4 μm or more, 0.5 μm or more, 0.6 μm or more, 0.7 μm or more, 0.8 μm or more, 0.9 μm or more, or 1 μm or more, and may be 50 μm or less, 47.5 μm or less, 45 μm or less, 42.5 μm or less, 40 μm or less, 38 μm or less, 36 μm or less, 34 μm or less, 32 μm or less, or 31 μm or less, but is not limited thereto.

[0160] In an exemplary embodiment, the average particle size of the fine dust may be 1 μm to 10 μm. For example, the average particle size of the fine dust may be 1 μm or more, 1.5 μm or more, 2 μm or more, 2.5 μm or more, 3 μm or more, 3.2 μm or more, 3.4 μm or more, 3.6 μm or more, 3.8 μm or more, 4 μm or more, 4.2 μm or more, 4.4 μm or more, 4.6 μm or more, 4.8 μm or more, 5 μm or more, 5.1 μm or more, 5.2 μm, 5.3 μm or more, 5.4 μm or more, 5.5 μm or more, 5.6 μm or more, 5.7 μm or more, or 5.8 μm or more, and 10 μm or less, 9.5 μm or less, 9 μm or less, 8.5 μm or less, 8 μm or less, 7.8 μm or less, 7.6 μm or less, 7.4 μm or less, It may be 7.2 μm or less, 7 μm or less, 6.9 μm or less, 6.8 μm or less, 6.7 μm or less, 6.6 μm or less, 6.5 μm or less, 6.4 μm or less, 6.3 μm or less, 6.2 μm or less, 6.1 μm or less, 6 μm or less, or 5.9 μm or less, but is not limited thereto.

[0161] In an exemplary embodiment, the fine dust may be ultrafine dust with an average particle size of 2.5 μm or less.

[0162] The care for skin damage caused by the aforementioned fine dust refers to effectively protecting skin cells from irritation and inhibiting, preventing, or repairing (restoring) changes in the expression levels of specific genes caused by said irritation. For example, the care for skin damage may be care for skin barrier damage, but is not limited thereto.

[0163] In an exemplary embodiment, the present disclosure provides a composition that inhibits damage to skin cells caused by fine dust by controlling the expression level of a specific gene or a specific protein in skin cells damaged by fine dust to a normal level.

[0164] In another aspect, the present disclosure provides a composition for improving skin sagging comprising a rose-derived peptide. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of a rose-derived peptide for the preparation of a composition for improving skin sagging.

[0165] The aforementioned skin sagging is a condition affected by gravity; preventing or improving sagging requires that the epidermal cells forming the epidermal layer be tightly stacked and that the epidermal and dermal layers be firmly connected. On the other hand, skin elasticity relates to the skin's restorative capacity and is associated with collagen in the dermal layer. As such, skin sagging, which is directly linked to the function of the epidermal-dermal junction (DEJ), is distinguished from skin elasticity.

[0166] In an exemplary embodiment, the composition may be characterized by restoring damage to the dermoepidermal junction.

[0167] The dermoepidermal junction (DEJ) is the connection site between the epidermis and dermis, playing a crucial role in the skin's structural integrity and function. The DEJ provides support to the epidermis and facilitates the transport of nutrients and metabolites between the dermis and epidermis. Structural changes in the DEJ can significantly affect the appearance and degree of skin sagging. The DEJ contains DEJ-specific structural proteins, COL7A1 and COL17A1, which contribute to the structural integrity of the DEJ. A decrease in these DEJ structural proteins weakens skin tension and leads to increased skin sagging. The DEJ structure is not flat but curved, a structure known as a rete ridge. Rete ridges increase the contact area between the epidermis and dermis and distribute physical loads applied to the epidermis, contributing to the bonding of the epidermal and dermal layers. In addition, it has been reported that changes in the expression of DEJ-specific structural proteins alter the Rete ridge structure, and there are reports that skin sagging improves when the expression of specific collagen proteins present in the DEJ is increased.

[0168] In an exemplary embodiment, the composition may be characterized by increasing the expression of collagen in the skin. The increase in collagen expression may include both an increase in the expression of the collagen gene and an increase in the synthesis of the collagen protein.

[0169] In an exemplary embodiment, the collagen may be collagen type Col7A1 or Col17A1.

[0170] In an exemplary embodiment, the composition may be applied to keratinocytes.

[0171] In an exemplary embodiment, the rose-derived peptide may be treated to cells at a concentration of 0.1 to 100 ppm (m / w). For example, the rose-derived peptide is 0.1 ppm (m / w) or more, 0.2 ppm (m / w) or more, 0.3 ppm (m / w) or more, 0.4 ppm (m / w) or more, 0.5 ppm (m / w) or more, 0.6 ppm (m / w) or more, 0.7 ppm (m / w) or more, 0.8 ppm (m / w) or more, 0.9 ppm (m / w) or more, 1 ppm (m / w) or more, 1.5 ppm (m / w) or more, 2 ppm (m / w) or more, 2.5 ppm (m / w) or more, 3 ppm (m / w) or more, 3.5 ppm (m / w) or more, 4 ppm (m / w) or more, 4.5 ppm (m / w) or more, 5 ppm (m / w) or more, 5.5 ppm (m / w) ≥, 6 ppm(m / w) or more, 6.5 ppm(m / w) or more, 7 ppm(m / w) or more, 7.5 ppm(m / w) or more, 8 ppm(m / w) or more, 8.5 ppm(m / w) or more, 9 ppm(m / w) or more, 9.It may be treated to cells at a concentration of 5 ppm (m / w) or higher or 10 ppm (m / w) or higher, and 100 ppm (m / w) or less, 95 ppm (m / w) or less, 90 ppm (m / w) or less, 85 ppm (m / w) or less, 80 ppm (m / w) or less, 75 ppm (m / w) or less, 70 ppm (m / w) or less, 65 ppm (m / w) or less, 60 ppm (m / w) or less, 55 ppm (m / w) or less, 50 ppm (m / w) or less, 45 ppm (m / w) or less, 40 ppm (m / w) or less, 35 ppm (m / w) or less, 30 ppm (m / w) or less, 28 ppm (m / w) or less, 26 ppm (m / w) or less, 24 Cells may be treated at concentrations of ppm(m / w) or less, 22 ppm(m / w) or less, 20 ppm(m / w) or less, 19 ppm(m / w) or less, 18 ppm(m / w) or less, 17 ppm(m / w) or less, 16 ppm(m / w) or less, 15 ppm(m / w) or less, 14 ppm(m / w) or less, 13 ppm(m / w) or less, 12 ppm(m / w) or less, 11 ppm(m / w) or less, 10.5 ppm(m / w) or 10 ppm(m / w) or less.

[0172] In an exemplary embodiment, the composition may be a pharmaceutical composition for the prevention or treatment of skin diseases caused by a decline in skin barrier function. For example, the skin disease caused by a decline in skin barrier function may be skin hypersensitivity, atopic dermatitis, senile dry skin, or xerosis. Skin hypersensitivity, atopic dermatitis, senile dry skin, or xerosis is a disease that may be caused by a decrease in the expression of collagen within skin cells due to damage to the skin barrier caused by external stimuli.

[0173]

[0174] In another aspect, the present disclosure provides a composition for anti-aging of the skin comprising a rose-derived peptide. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of the rose-derived peptide for the preparation of a composition for anti-aging of the skin.

[0175] The aforementioned skin reverse aging refers to a biological phenomenon that restores skin structure and function damaged or degraded by aging to a youthful state. This is distinct from "anti-aging," which merely slows down the aging process, and is a concept that includes active improvement actions to induce physiological recovery in skin cells or tissues that have already aged.

[0176] In an exemplary embodiment, the skin anti-aging may be the rejuvenation of aged skin cells. Alternatively, it may be the restoration of senescent cells with cell cycle arrest to a cell cycle level similar to that of young cells. Alternatively, it may be the regrowth of senescent cells whose growth has been inhibited.

[0177] The aforementioned aged cells refer to the aged state of all types of skin cells known to those skilled in the art. On the other hand, young cells refer to a state in which cells have not lost their normal proliferative capacity, continuing the cell cycle or in a state where the cell cycle has not stopped.

[0178] The above anti-aging means the reversal or alleviation of the aging process, or any other process that can damage macromolecules, cells, tissues, and organs, including the skin, or cause the accumulation of damage (e.g., abrasions caused by falls, burns, etc.).

[0179] In an exemplary embodiment, the anti-aging may include one or more selected from the group consisting of increased skin moisturizing ability, strengthening of the epidermal barrier, improvement of cell division ability, normalization of epidermal differentiation, increased skin regeneration ability, improvement of keratin shedding control, strengthening of intercellular adhesion, and inhibition of substrate-degrading enzyme activity.

[0180] In an exemplary embodiment, the composition can improve one or more phenomena selected from the group consisting of a decrease in basal layer cell density of the skin induced by aging, indistinctness of intercellular boundaries, absence of keratohyalin granules, and persistence of nuclei within the stratum corneum.

[0181] In an exemplary embodiment, the composition may increase the mRNA expression of one or more selected from the group consisting of Col17a (Collagen type XVII alpha 1 chain), FLG (Filaggrin), KLK5 (Kallikrein-related peptidase 5), KRT10 (Keratin 10), SOX2 (SRY-Box Transcription Factor 2), and CLDN1 (Claudin-1), or decrease the mRNA expression of p16 (Cyclin-dependent kinase inhibitor 2A) or MMP-2 (Matrix Metallopeptidase 2).

[0182] In an exemplary embodiment, the skin may be a keratinocyte.

[0183] In an exemplary embodiment, the amount of the rose-derived peptide applied may be 0.0001 to 10 g / kg / day. For example, the amount of the rose-derived peptide applied may be 0.0001 g / kg / day or more, 0.0005 g / kg / day or more, 0.001 g / kg / day or more, 0.005 g / kg / day or more, 0.01 g / kg / day or more, 0.05 g / kg / day or more, 0.1 g / kg / day or more, 0.5 g / kg / day or more, 1 g / kg / day or more, or 5 g / kg / day or more, and may be 10 g / kg / day or less, 8 g / kg / day or less, 6 g / kg / day or less, 4 g / kg / day or less, 2 g / kg / day or less, 1 g / kg / day or less, 0.5 g / kg / day or less, or 0.1 g / kg / day or less, but is not limited thereto.

[0184] In an exemplary embodiment, the rose-derived peptide may be a peptide obtained by adding an enzyme to a rose-derived protein. For example, the rose-derived protein may be derived from the rose extract, but is not limited thereto. Also, for example, the enzyme may be a cysteine ​​protease, but is not limited thereto. Also, for example, the enzyme may be a plant-derived enzyme, but is not limited thereto. Also, for example, the plant-derived enzyme may be bromelain, may be pineapple-derived bromelain, or may be pineapple stem-derived bromelain, but is not limited thereto. Bromelain is a type of protease that hydrolyzes peptide bonds of proteins / polypeptides. Furthermore, the protease is distinguished from cellulose, which is an enzyme that hydrolyzes the β-1,4 bonds of high molecular weight cellulose into glucose, and pectin, which is an enzyme that hydrolyzes the glycosidic bonds of pectin (a polysaccharide). In addition, the above bromelain is an enzyme class cysteine ​​protease, has an active center of a cysteine ​​residue (Cys-His-Asp), an optimal pH of 5.0-7.0, a molecular weight of 24.5-37 kDa, and may be derived from pineapple. Therefore, the above bromelain is distinguished from pepsin (enzyme class: aspartate protease, active center: two aspartate residues, optimal pH: 1.5-2.5, molecular weight: ~35 kDa) and neutral protease (enzyme class: metalloprotease, active center: metal ion, optimal pH: 6.0-8.5, molecular weight: ~36 kDa).

[0185] In an exemplary embodiment, the composition may be one or more pharmaceutical compositions for prevention or treatment selected from the group consisting of atopic dermatitis, seborrheic dermatitis, diabetic ulcer, basal cell carcinoma, and squamous cell carcinoma.

[0186]

[0187] In another aspect, the present disclosure provides an antiglycation composition comprising a rose-derived peptide. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of the rose-derived peptide for the preparation of an antiglycation composition.

[0188] The aforementioned anti-glycation refers to the process in which proteins, lipids, nucleic acids, etc., in the body non-enzymatically bind with sugars (such as glucose) to form Advanced Glycation End Products (AGEs); in other words, it refers to inhibiting or slowing down glycation.

[0189] In another aspect, the present disclosure provides a composition for improving skin tone comprising a rose-derived peptide. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of the rose-derived peptide for the preparation of a composition for improving skin tone.

[0190] The above skin tone is the sum of the hue and brightness visible on the skin surface, and refers to the overall color of the skin that reflects the complex combination of melanin, blood vessels, collagen, and the condition of the stratum corneum. For example, skin color is generally expressed as L, a, and b* values ​​in the CIE Lab color space, where L* represents lightness, a* represents the red-green axis, and b* represents the yellow-blue axis. The rose-derived peptide of the present disclosure has excellent anti-glycation efficacy, so it can improve the yellow tone or yellowness of the skin, that is, improve the b* value.

[0191] In an exemplary embodiment, the composition can inhibit the formation of advanced glycation end products.

[0192] In an exemplary embodiment, the skin tone improvement may be an improvement of the yellow tone of the skin or skin yellowing.

[0193] The above yellow tone refers to a condition in which the surface of the skin appears generally dull and yellowish. The above skin yellowing refers to a phenomenon in which the skin turns yellow overall, losing vitality and transparency, and giving a dull and dark impression.

[0194] In an exemplary embodiment, the rose-derived peptide may be treated to cells at a concentration of 15 to 10,000 ppm (w / v). For example, the above rose-derived peptide is treated to cells at a concentration of 15 ppm (w / v) or more, 17 ppm (w / v) or more, 19 ppm (w / v) or more, 20 ppm (w / v) or more, 21 ppm (w / v) or more, 22 ppm (w / v) or more, 23 ppm (w / v) or more, or 24 ppm (w / v) or more, or 10,000 ppm (w / v) or less, 5,000 ppm (w / v) or less, 1,000 ppm (w / v) or less, 900 ppm (w / v) or less, 800 ppm (w / v) or less, 700 ppm (w / v) or less, 600 ppm (w / v) or less, 500 ppm (w / v) or less, 400 ppm (w / v) or less, 300 ppm (w / v) or less, Cells may be treated at concentrations of 200 ppm (w / v) or less, 150 ppm (w / v) or less, or 125 ppm (w / v) or less, but are not limited thereto.

[0195] In an exemplary embodiment, the amount of the rose-derived peptide applied may be 0.0001 to 10 g / kg / day. For example, the amount of the rose-derived peptide applied may be 0.0001 g / kg / day or more, 0.0005 g / kg / day or more, 0.001 g / kg / day or more, 0.005 g / kg / day or more, 0.01 g / kg / day or more, 0.05 g / kg / day or more, 0.1 g / kg / day or more, 0.5 g / kg / day or more, 1 g / kg / day or more, or 5 g / kg / day or more, and may be 10 g / kg / day or less, 8 g / kg / day or less, 6 g / kg / day or less, 4 g / kg / day or less, 2 g / kg / day or less, 1 g / kg / day or less, 0.5 g / kg / day or less, or 0.1 g / kg / day or less, but is not limited thereto.

[0196] In an exemplary embodiment, the composition may be a pharmaceutical composition for the prevention or treatment of skin diseases caused by glycation. For example, the composition may be a pharmaceutical composition for the prevention or treatment of diabetic dermopathy, diabetic necrotizing lipoidica, arteriosclerosis, or Alzheimer's disease. For example, if AGEs accumulate in the skin, regenerative capacity may decrease due to the glycation of collagen and elastin, which may lead to diabetic dermopathy, and if the inflammatory response intensifies, diabetic necrotizing lipoidica may occur, but is not limited thereto. Additionally, for example, AGEs may accumulate in blood vessels, weakening vascular elasticity and promoting arteriosclerosis, and AGEs may accumulate in brain nerve cells, causing an inflammatory response and leading to a decline in brain function, but are not limited thereto.

[0197]

[0198] In another aspect, the present disclosure provides a composition for preventing hair loss or promoting hair growth comprising a rose-derived peptide. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of a rose-derived peptide for the preparation of a composition for preventing hair loss or promoting hair growth.

[0199] The above-mentioned hair loss refers to the phenomenon of hair (e.g., hair, eyebrows, eyelashes, etc.) falling out from the body (e.g., scalp, skin) or the phenomenon of hair thinning, and "hair loss prevention" refers to preventing and suppressing the hair loss phenomenon described above.

[0200] The above hair growth promotion refers not only to a hair growth function that generates new hair (e.g., hair, eyebrows, eyelashes, etc.) or promotes hair growth, but also to a function that promotes delaying the transition from the growth phase to the regression phase of the hair cycle and enables existing hair to grow healthily. In the present disclosure, hair growth promotion may be used in combination with "hair growth promotion."

[0201] The hair cycle can be divided into three major phases known as the growth phase, the regression phase, and the resting phase. During the growth phase, hair formation occurs as the hair follicle grows deep into the skin accompanied by rapid cell proliferation. The regression phase is a transitional period characterized by a prominent cessation of cell division; during this process, the hair follicle gradually regresses, and hair growth ceases. In the resting phase, the regressing follicle contains a germ with densely packed dermal papilla cells. The initiation of a new growth phase from the resting phase is induced by rapid cell proliferation in the germ, expansion of the dermal papilla, and synthesis of basement membrane elements. Typically, hair growth occurs during the growth phase, and it can be promoted by induction from the resting phase to the growth phase or delay from the growth phase to the regression phase.

[0202] In the present disclosure, the term “hair” may include not only hair on the head but also all hair growing on various parts of an individual (e.g., mammals). For example, in the present disclosure, hair may include, but is not limited to, at least one selected from the group consisting of hair, eyebrows, eyelashes, and body hair (e.g., chest hair, leg hair). Hair is a keratinized fibrous structure growing from the epidermal layer of the skin and may primarily serve protective and sensory functions. For example, hair protects the scalp and helps regulate body temperature, while eyebrows and eyelashes may serve to protect the eyes from dust or sweat.

[0203] For example, a composition according to one aspect of the present disclosure may induce and / or promote growth of at least one length selected from the group consisting of hair, eyebrows and eyelashes, but is not limited thereto. A composition according to one aspect of the present disclosure may be applied to hair, eyebrows and / or eyelashes.

[0204] In another aspect, the present disclosure provides a composition for strengthening hair roots comprising a rose-derived peptide. The rose-derived peptide is as described above. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of a rose-derived peptide for the preparation of a composition for strengthening hair roots.

[0205] The aforementioned hair root strengthening refers to the action of reinforcing the structure of the hair root, including the hair papilla and outer root sheath, so that the hair is more firmly anchored to the scalp, and improving the function of hair follicle cells to increase resistance to hair shedding.

[0206] For example, a composition according to one aspect of the present disclosure may induce and / or promote growth of at least one length selected from the group consisting of hair, eyebrows and eyelashes, but is not limited thereto. A composition according to one aspect of the present disclosure may be applied to hair, eyebrows and / or eyelashes.

[0207] In another aspect, the present disclosure provides a composition for promoting eyelash growth comprising a rose-derived peptide. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of a rose-derived peptide for the preparation of a composition for promoting eyelash growth.

[0208] The above eyelash growth promotion refers to the action of increasing the length, thickness, and density of the eyelashes and extending the anagen phase of the eyelashes by inducing the proliferation or activation of hair follicle cells that form the eyelashes.

[0209] In an exemplary embodiment, the composition may further include acetyl dipeptide-1 cetyl ester.

[0210] In an exemplary embodiment, the composition may contain the rose-derived peptide and the acetyldipeptide-1-cetyl ester in a weight ratio of 1 to 100:1. For example, the composition may contain the rose-derived peptide and the acetyldipeptide-1-cetyl ester in a ratio of 1 to 100:1, 1 to 90:1, 1 to 80:1, 1 to 70:1, 1 to 60:1, 1 to 50:1, 1 to 40:1, 1 to 30:1, 2 to 30:1, 3 to 30:1, 4 to 25:1, 5 to 20:1, 5 to 15:1, 6 to 14:1, 7 to 13:1, 8 to 12:1, or 9 to 11:1, but is not limited thereto.

[0211] In an exemplary embodiment, the composition may contain 0.00001 to 0.1 weight% of the rose-derived peptide or 0.000001 to 0.01 weight% of the acetyl dipeptide-1-cetyl ester. For example, the above composition may contain the rose-derived peptide in an amount of 0.00001 wt% or more, 0.00005 wt% or more, 0.0001 wt% or more, 0.0002 wt% or more, 0.0004 wt% or more, 0.0006 wt% or more, 0.0008 wt% or more, 0.0009 wt% or more, or 0.1 wt% or less, 0.05 wt% or less, 0.01 wt% or less, 0.008 wt% or less, 0.006 wt% or less, 0.004 wt% or less, or 0.002 wt% or less, but is not limited thereto. In addition, for example, the composition may contain the acetyl dipeptide-1-cetyl ester in an amount of 0.000001 wt% or more, 0.000005 wt% or more, 0.00001 wt% or more, 0.00002 wt% or more, 0.00004 wt% or more, 0.00006 wt% or more, 0.00008 wt% or more, 0.00009 wt% or more, or 0.01 wt% or less, 0.005 wt% or less, 0.001 wt% or less, 0.0008 wt% or less, 0.0006 wt% or less, 0.0004 wt% or less, or 0.0002 wt% or less, but is not limited thereto.

[0212] In an exemplary embodiment, the cell throughput of the rose-derived peptide may be 0.1 to 1000 ppm (w / v), or the cell throughput of the acetyl dipeptide-1-cetyl ester may be 0.01 to 100 ppm (w / v). For example, the cell throughput of the rose-derived peptide may be 0.1 ppm (w / v) or more, 0.5 ppm (w / v) or more, 1 ppm (w / v) or more, 2 ppm (w / v) or more, 4 ppm (w / v) or more, 6 ppm (w / v) or more, 8 ppm (w / v) or more, or 9 ppm (w / v) or more, and may be 1000 ppm (w / v) or less, 500 ppm (w / v) or less, 100 ppm (w / v) or less, 80 ppm (w / v) or less, 60 ppm (w / v) or less, 40 ppm (w / v) or less, 30 ppm (w / v) or less, 20 ppm (w / v) or less, or 15 ppm (w / v) or less.

[0213] In an exemplary embodiment, the amount of the rose-derived peptide applied may be 0.0001 to 10 g / kg / day. For example, the amount of the rose-derived peptide applied may be 0.0001 g / kg / day or more, 0.0005 g / kg / day or more, 0.001 g / kg / day or more, 0.005 g / kg / day or more, 0.01 g / kg / day or more, 0.05 g / kg / day or more, 0.1 g / kg / day or more, 0.5 g / kg / day or more, 1 g / kg / day or more, or 5 g / kg / day or more, and may be 10 g / kg / day or less, 8 g / kg / day or less, 6 g / kg / day or less, 4 g / kg / day or less, 2 g / kg / day or less, 1 g / kg / day or less, 0.5 g / kg / day or less, or 0.1 g / kg / day or less, but is not limited thereto.

[0214] In an exemplary embodiment, the composition can proliferate dermal papilla cells or inhibit the death of outer root sheath cells.

[0215] In an exemplary embodiment, the composition may be for cosmetic use.

[0216] In an exemplary embodiment, the formulation of the cosmetic may be one selected from the group consisting of hair tonic, hair conditioner, hair essence, hair lotion, hair nourishing lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nourishing cream, hair moisture cream, hair massage cream, hair wax, hair aerosol, hair pack, hair nourishing pack, hair soap, hair cleansing foam, hair drying agent, hair preservative, hair dye, hair wave agent, hair bleaching agent, hair gel, hair glaze, hair dressing agent, hair lacquer, hair moisturizer, hair mousse, hair spray, eyebrow growth agent, eyelash growth agent, and eyelash nourishing agent.

[0217] In an exemplary embodiment, the composition may be a pharmaceutical composition for preventing or treating hair loss.

[0218]

[0219] In another aspect, the present disclosure provides a composition for improving skin barrier function, comprising a rose-derived peptide, wherein the skin is damaged by an exosome. The rose-derived peptide is as described above. Additionally, the present disclosure provides a use of a rose-derived peptide for preparing a composition for improving skin barrier function damaged by an exosome.

[0220] The aforementioned skin barrier refers to a physiological defense system in which the stratum corneum, the outermost layer of the skin, and its sub-structures form a physical, chemical, and immunological defense system to protect the body from harmful external environments and prevent the loss of internal moisture. In particular, keratinocytes in the epidermal layer and the stratum corneum formed by them play a central role in the structural and functional defense of the skin barrier.

[0221] The aforementioned exosome is an organic whole of environmental factors rather than genetic ones, containing complex factors that directly or indirectly affect skin health and function. For example, these include increased cortisol levels due to mental stress, exposure to blue light, and hormonal changes; these factors can contribute to the deterioration of skin condition by causing physiological changes such as inhibition of keratinocyte differentiation, impaired skin barrier function, reduced moisturization, and induction of inflammatory responses.

[0222] In an exemplary embodiment, the exosome may be mental stress or blue light.

[0223] In an exemplary embodiment, the mental stress may be stress caused by glucocorticoid hormones. For example, the mental stress may be a response caused by glucocorticoid hormones that naturally rise in response to mental stimulation, or the mental stress may be a response caused by cortisol that naturally rises in response to mental stimulation, but is not limited thereto. Additionally, for example, the mental stress may be a response induced by externally treating cortisol, but is not limited thereto.

[0224] In an exemplary embodiment, the glucocorticoid hormone may be one or more selected from cortisol, cortisone, and corticosterone.

[0225] In an exemplary embodiment, the wavelength of the blue light may be 380 to 500 nm. For example, the wavelength of the blue light may be 380 nm or more, 390 nm or more, 400 nm or more, 410 nm or more, 420 nm or more, 430 nm or more, 440 nm or more, or 445 nm or more, and may be 500 nm or less, 440 nm or less, 430 nm or less, 420 nm or less, 410 nm or less, or 405 nm or less, but is not limited thereto.

[0226] In an exemplary embodiment, the improvement of the skin barrier function may be one or more selected from the group consisting of promoting differentiation of keratinocytes, promoting intercellular binding of keratinocytes, and improving skin hydration.

[0227] In an exemplary embodiment, the composition can promote the expression of one or more mRNAs selected from the group consisting of KRT1 (Keratin 1), KRT10 (Keratin 10), FLG (Filaggrin), LOR (Loricrin), CASP14 (Caspase 14), CLDN1 (Claudin 1) and TJP1 (Tight Junction Protein 1).

[0228] In an exemplary embodiment, the composition may be applied to the epidermal layer of the skin.

[0229] In an exemplary embodiment, the composition may be applied to keratinocytes.

[0230] In an exemplary embodiment, the rose-derived peptide may be treated to cells at a concentration of 0.1 to 100 ppm (w / v). For example, the above rose-derived peptide is treated to cells at a concentration of 0.1 ppm (w / v) or more, 0.2 ppm (w / v) or more, 0.3 ppm (w / v) or more, 0.4 ppm (w / v) or more, 0.5 ppm (w / v) or more, 0.6 ppm (w / v) or more, 0.7 ppm (w / v) or more, 0.8 ppm (w / v) or more, or 0.9 ppm (w / v) or more, or 100 ppm (w / v) or less, 90 ppm (w / v) or less, 80 ppm (w / v) or less, 70 ppm (w / v) or less, 60 ppm (w / v) or less, 50 ppm (w / v) or less, 40 ppm (w / v) or less, 30 ppm (w / v) or less, 20 ppm (w / v) or less, 18 Cells may be treated at concentrations of ppm (w / v) or less, 16 ppm (w / v) or less, 14 ppm (w / v) or less, 13 ppm (w / v) or less, 12 ppm (w / v) or less, or 11 ppm (w / v) or less, but are not limited thereto.

[0231] In an exemplary embodiment, the composition may contain 0.000001 to 0.1 weight% of the rose-derived peptide. For example, the composition may contain 0.000001 weight% or more, 0.00001 weight% or more, 0.0001 weight% or more, 0.001 weight% or more, 0.001 weight% or more, or 0.1 weight% or more of the rose-derived peptide, and may contain 0.1 weight% or less, 0.01 weight% or less, 0.001 weight% or less, 0.0001 weight% or less, 0.00001 weight% or less, or 0.000001 weight% or less, but is not limited thereto.

[0232] In an exemplary embodiment, the composition may be a pharmaceutical composition for the prevention or treatment of skin diseases caused by impaired skin barrier function. For example, the skin disease caused by impaired skin barrier function may be any one selected from the group consisting of atopic dermatitis, psoriasis, acne, and seborrheic dermatitis, but is not limited thereto.

[0233]

[0234] In another aspect, the present disclosure may provide a method for preparing the peptide or the composition, comprising the steps of: preparing a rose (Rosa damascena) extract; precipitating a rose-derived protein from the rose extract; treating the rose-derived protein with a protease to hydrolyze it; and inactivating the protease.

[0235] For example, the step of preparing the rose extract may involve extracting the rose raw material in hot water at a ratio of 10 or more, 20 or more, 30 or more, or 40 or more, and extracting at a temperature of 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher for 20 minutes or more, 30 minutes or more, 40 minutes or more, 50 minutes or more, or 1 hour or more, but is not limited thereto.

[0236] In an exemplary embodiment, the average molecular weight may be 3000 Da or less. For example, the average molecular weight may be 3000 Da or less, 2800 Da or less, 2600 Da or less, 2400 Da or less, 2000 Da or less, 1900 Da or less, 1800 Da or less, 1700 Da or less, 1600 Da or less, 1500 Da or less, 1400 Da or less, 1300 Da or less, 1200 Da or less, 1100 Da or less, or 1000 Da or less.

[0237]

[0238] In an exemplary aspect, the preparation of the rose (Rosa damascena) extract may be carried out by hot water extraction of rose flowers, or the precipitation of the rose-derived protein may be carried out by adjusting the pH of the rose extract to 8 or higher to induce elution, and then adjusting the pH to 5 or lower.

[0239] According to an exemplary embodiment, the preparation of the rose (Rosa damascena) extract may include a step of adjusting the pH to 8 or higher after hot water extraction of the rose flower to induce the elution of a rose-derived protein.

[0240] For example, extraction may be performed by adding purified water at least 1, 2, 4, 6, 8, or 10 times the weight of the dried rose petals, and the extraction may be performed at a temperature of at least 60°C, 65°C, 70°C, 75°C, or 80°C for at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, or at least 1 hour, but is not limited thereto.

[0241] The method of adjusting the above pH to 8 or higher may involve using a basic solution containing NaOH, but is not limited thereto. For example, the above pH may be 8 or higher, 8.5 or higher, 9 or higher, 9.5 or higher, or 10 or higher, but is not limited thereto.

[0242] In addition, after the protein elution, the pH can be adjusted to 5 or lower to precipitate the protein, and then the precipitated protein can be obtained by centrifugation. At this time, the method of adjusting the pH to 5 or lower may be to use an acidic solution containing HCl, but is not limited thereto. In addition, for example, the pH may be 5 or lower, 4.8 or lower, 4.6 or lower, 4.4 or lower, 4.2 or lower, or 4 or lower, but is not limited thereto.

[0243] In addition, the centrifugation may be performed at 2000 rpm or more, 2500 rpm or more, 3000 rpm or more, 3500 rpm or more, or 4000 rpm or more, but is not limited thereto. In addition, the centrifugation may be performed for 10 minutes or more, 15 minutes or more, 20 minutes or more, 25 minutes or more, or 30 minutes or more, or for 50 minutes or less, 45 minutes or less, 40 minutes or less, 35 minutes or less, or 30 minutes or less, but is not limited thereto.

[0244] After adding distilled water to the obtained precipitate, the enzyme reaction is carried out by neutralizing it to the optimal pH of each enzyme using NaOH. Subsequently, heating may be performed to inactivate the enzyme, but the process for inactivating the enzyme is not limited to this.

[0245] In an exemplary aspect, the method may further include a step of neutralizing the protein by adjusting the pH of the rose extract to 6 to 8 after the step of precipitating the protein and before the step of hydrolyzing the protein.

[0246] For example, the pH of the neutralization step may be adjusted to 6 to 8, and the pH may be adjusted to 6 or higher, 6.2 or higher, 6.4 or higher, 6.6 or higher, 6.8 or higher, or 7 or higher, or adjusted to 8 or lower, 7.8 or higher, 7.6 or lower, 7.4 or lower, 7.2 or lower, or 7 or lower, but is not limited thereto.

[0247] Additionally, for example, the enzyme reaction may be a hydrolysis reaction. The hydrolysis may be performed at 45 to 60°C, or at 45°C or higher, 46°C or higher, 47°C or higher, 48°C or higher, 49°C or higher, or 50°C or higher, or at 60°C or lower, 59°C or lower, 58°C or lower, 57°C or lower, 56°C or lower, or 55°C or lower, but is not limited thereto. Additionally, the hydrolysis may be performed for several minutes or more, several hours or more, or tens of hours or more, but is not limited thereto.

[0248] In an exemplary aspect, the step of inactivating the proteolytic enzyme may be performed at 75 to 95 ℃, and the step may be performed at 75 ℃ or higher, 77.5 ℃ or higher, 80 ℃ or higher, 82.5 ℃ or higher, or 85 ℃ or higher, or at 95 ℃ or lower, 92.5 ℃ or lower, 90 ℃ or lower, 87.5 ℃ or lower, or 85 ℃ or lower, but is not limited thereto. Additionally, the step may be performed for 10 to 30 minutes, and the process may be performed for 10 minutes or more, 12 minutes or more, 14 minutes or more, 16 minutes or more, 18 minutes or more, or 20 minutes or more, or for 30 minutes or less, 28 minutes or less, 26 minutes or less, 24 minutes or less, 22 minutes or less, or 20 minutes or less, but is not limited thereto.

[0249]

[0250] In another aspect, the present disclosure may provide a rose-derived peptide prepared by the above method as the peptide. The method for preparing the rose-derived peptide and the rose-derived peptide are as described above.

[0251] In another aspect, the present disclosure may provide a composition prepared by a method comprising the following steps as the composition: preparing a rose (Rosa damascena) extract; precipitating a rose-derived protein from the rose extract; treating the rose-derived protein with a protease to hydrolyze it; and inactivating the protease. The method for preparing the rose-derived peptide and the rose-derived peptide are as described above.

[0252]

[0253] The present disclosure may provide the following embodiments as one example.

[0254]

[0255] The first embodiment may provide a peptide comprising or composed of one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5.

[0256] A second embodiment may provide a peptide according to a first embodiment, which is (a) derived from rose flowers and / or (b) derived from a water extract of rose flowers and / or (c) obtained by treating a rose-derived protein extract with a plant-derived enzyme, wherein the enzyme is preferably cysteine ​​protease and more preferably bromelain.

[0257] A third embodiment may provide a composition comprising one or more peptides according to a first or second embodiment, wherein the composition is preferably a rose flower extract.

[0258] The fourth embodiment may provide a non-therapeutic cosmetic use for skin improvement of the composition according to the third embodiment, wherein the skin improvement may be one or more of skin aging improvement, antioxidant, skin damage care, skin sagging improvement, skin anti-aging, anti-glycation, skin tone improvement, prevention of hair loss or promotion of hair growth, strengthening of hair roots, and promotion of eyelash growth.

[0259] The fifth embodiment may provide a use in the fourth embodiment, wherein (a) the skin aging improvement is to improve skin wrinkles, elasticity, or keratinization, or to inhibit the secretion of neurotransmitters, or to inhibit the expression of collagenases, and / or (b) the composition is applied to skin fibroblasts and / or keratinocytes, and / or (c) the skin damage improvement or sagging improvement is to restore damage at the dermal-epidermal junction, or to increase collagen expression within the skin, and / or (d) the skin damage is skin damage caused by fine dust.

[0260] The sixth embodiment may provide a use in which, in the fifth embodiment, the neurotransmitter is noradrenaline and / or, the collagenase is MMP-1 and / or, and the collagen is Col7A1 or Col17A1.

[0261] The seventh embodiment may provide a use in any one of the fourth to sixth embodiments, wherein (a) the anti-aging includes one or more of the following: increased skin moisturizing ability, strengthening of the epidermal barrier, improved cell division ability, normalization of epidermal differentiation, increased skin regeneration ability, improved control of exfoliation, strengthening of intercellular adhesion, or inhibition of substrate degrading enzyme activity; and / or (b) the anti-aging improves one or more of the following: reduced cell density of the skin basal layer induced by aging, indistinctness of intercellular boundaries, absence of keratohyalin granules, and retention of nuclei within the stratum corneum; and / or (c) the anti-aging increases the expression of one or more mRNAs selected from the group consisting of Col17A1, FLG, KLK5, KRT10, SOX2, and CLDN1, or decreases the expression of p16 and / or MMP-2.

[0262] The eighth embodiment may provide an use in any one of the fourth to seventh embodiments, wherein (a) the anti-glycation or skin tone improvement inhibits the formation of advanced glycation products (AGEs) and / or, (b) the skin tone improvement improves the yellow tone of the skin or skin yellowing and / or, and (c) the rose-derived peptide is treated to cells at a concentration of 0.25 to 10,000 ppm (w / v).

[0263] The ninth embodiment may provide a use in any one of the fourth to eighth embodiments, wherein the skin improvement is one or more of preventing hair loss, promoting hair growth, strengthening hair roots, or promoting eyelash growth, and the composition further comprises acetyl dipeptide-1 cetyl ester.

[0264] The 10th embodiment may provide a use in the 9th embodiment, wherein (a) the composition comprises a rose-derived peptide and an acetyl dipeptide-1 cetyl ester in a weight ratio of 1 to 100:1 and / or (b) the composition comprises a rose-derived peptide in an amount of 0.00001 to 0.1 wt% and an acetyl dipeptide-1 cetyl ester in an amount of 0.000001 to 0.01 wt% and / or (c) the rose-derived peptide is treated to cells at a concentration of 0.1 to 1,000 ppm (w / v) and an acetyl dipeptide-1 cetyl ester is treated at a concentration of 0.01 to 100 ppm (w / v), and / or (d) the skin improvement includes inhibiting dermal papilla cell proliferation or outer root sheath cell death.

[0265] 11th Embodiment: The composition according to the 3rd embodiment may be a therapeutic or non-therapeutic composition for skin improvement. For example, the skin improvement may be the improvement of damaged skin barrier function by an exposome, or the skin improvement may be the improvement of damaged skin barrier function by an exposome and (a) the exposome is mental stress and / or blue light and / or (b) the improvement of damaged skin barrier function by the exposome includes the promotion of differentiation of keratinocytes, the promotion of intercellular binding, and / or improvement of skin hydration, and / or (c) the improvement of damaged skin barrier function by the exposome promotes mRNA expression of one or more of KRT1, KRT10, FLG, LOR, CASP14, CLDN1 and TJP1, and / or (d) the composition is applied to the epidermal layer of the skin and / or (e) the rose-derived peptide is treated to cells at a concentration of 0.1 to 100 ppm (w / v).

[0266] The 12th embodiment can provide an application in which, in the 11th embodiment, the mental stress is caused by a glucocorticoid hormone and the wavelength of the blue light is 380 to 500 nm.

[0267] The 13th embodiment may provide a method for preparing a peptide of the 1st or 2nd embodiment or a rose-derived extract of the 3rd embodiment, comprising the following steps: preparing a water-soluble extract of rose (Rosa damascena); precipitating a rose-derived protein from the extract; hydrolyzing the rose-derived protein by treating it with a protease; and inactivating the protease.

[0268] The 14th embodiment may provide a method for manufacturing characterized in that, in the 13th embodiment, the preparation of the rose (Rosa damascena) extract is performed by hot-water extraction of rose petals, the elution of the rose-derived protein is performed by adjusting the pH of the rose extract to 8 or higher, and further includes a step of adjusting the pH of the rose extract to 5 or lower to precipitate the protein, or further includes a step of neutralizing the protein by adjusting the pH to 6 to 8 before hydrolysis after precipitation.

[0269] The 15th embodiment may provide a peptide that is a rose-derived peptide prepared by the method of the 13th or 14th embodiment, as the peptide of the 1st or 2nd embodiment.

[0270] The 16th embodiment may provide a rose-derived extract of the 3rd embodiment, wherein the rose-derived extract comprises a rose-derived peptide prepared by the method of the 13th or 14th embodiment.

[0271]

[0272] The present disclosure is to be explained in more detail below through examples and the like. These examples are solely for the purpose of illustrating the present disclosure, and it will be obvious to those skilled in the art that the scope of the present disclosure is not to be interpreted as being limited by these examples.

[0273]

[0274] Preparation Example

[0275]

[0276] 1. Preparation of a composition containing rose-derived peptides

[0277] The extraction and isolation method for rose-derived peptides is as follows. Distilled water is added to dried flower petals of the Damask rose (Rosa damascenaflower), and the mixture is extracted at 80°C for 1 hour. Then, sodium hydroxide is added to adjust the pH to 10, and the mixture is left to stand at 25°C for 3 hours to elute the protein. Subsequently, hydrochloric acid is added to adjust the pH to 4 and reacted for 30 minutes to induce protein coagulation. Afterward, the protein is centrifuged using a centrifuge (model name: Centrifuge 5910, manufacturer: Eppendorf) at 4,000 rpm for 30 minutes to precipitate the protein.

[0278] Distilled water and sodium hydroxide were added to the obtained precipitate to neutralize it to pH 7, after which 10 units of each enzyme were added and hydrolysis was carried out at 50–55°C for several hours. The enzymes used were a plant-derived enzyme (Bromelain from pineapple stem, Sigma-Aldrich), a fungal-derived enzyme (Flavourzyme®, Novonesis), and a microbial-derived enzyme (Protamex®, Novonesis), respectively. Subsequently, the enzymes were inactivated by heating at 85°C for 20 minutes, and the dried product was obtained to measure the total peptide content in the solid. The total amount of peptides in the solid was quantitatively analyzed using Pierce™ Quantitative Peptide Assays & Standards (Manufacturer: Thermo Scientific™), and it was confirmed that the solid contained more than 80% peptides.

[0279] The sequence of the rose-derived peptide contained in the above rose-derived peptide extract was analyzed through the following steps.

[0280] 1) The obtained peptides were freeze-dried and dissolved in water for analysis, or used for analysis after SPE treatment, and LC-MS / MS analysis was performed. The equipment and analysis conditions used are as shown in Table 1 below.

[0281]

[0282] LC-MS SystemBioAccord LC-MS System with ACQUITY Premier BSMColumnACQUITY Premier HSS T3 2.1 with fragmentationPolarityPositive(1kV, 20V, 40-60V) Negative (0.8kV, 15V, 50-70V)Scan Rate5 HZ

[0283] 2) The amino acid sequence of a rose-derived peptide produced by a plant-derived enzyme according to one embodiment of the present disclosure, analyzed using a database on the spectrum file obtained through LC-MS / MS analysis in 1), is as shown in Table 2 below.

[0284]

[0285] Peptide amino acid sequence Sequence number SSANGPLGGGAGM Sequence number 1RGMSPGGGGGGGL Sequence number 2STGANLAAASNP Sequence number 3STENLGGGGVAN Sequence number 4TSNGALGGVSPN Sequence number 5

[0286]

[0287] [Experimental Example 1: Composition for improving skin aging containing a novel peptide]

[0288] 1. Confirmation of antioxidant efficacy of rose-derived peptide composition

[0289] Antioxidant efficacy, which maintains an antioxidant state by protecting the human body from oxidative stress through the removal of free radicals of reactive oxygen species, is known as a fundamental principle related to skin aging. Accordingly, in this experiment, an antioxidant efficacy experiment was conducted as follows using a rose hot water extract obtained by extracting Damask roses with 80°C water and three types of rose-derived peptides with different peptide sequences prepared using different enzymes.

[0290] 1-1. Evaluation of Antioxidant Efficacy

[0291] The 1,1-diphenyl-2-pocrylhydrochloride (DPPH) and ascorbic acid used in the experiment were purchased from MERCK (USA). 247.5 µl of DPPH solution dissolved in ethanol was dispensed into 96-well plates using a µl-t-channel pipette, and 2.5 µl of the sample was added to make the final reaction solution 250 µl. After reacting for a certain period of time, the change in absorbance at 517 nm was measured using a microplate reader (Bio-Rad), and the free radical scavenging activity was determined by comparing the values ​​of the control group and the treatment group.

[0292] To determine the optimal reaction time for measuring free radical scavenging activity, the DPPH concentration was fixed at 100 µM (pH 7.8), and then ascorbic acid concentrations of 10, 30, and 50 µM were applied, and the change in absorbance after 30 minutes was investigated.

[0293] The DPPH radical scavenging rate was calculated using the following formula.

[0294] DPPH radical scavenging activity (%)= {1-(S-SB) / (C-CB)} ×100

[0295] S: Absorbance of sample, SB: Absorbance of sample blank, C: Absorbance of ethanol, CB: Absorbance of ethanol blank

[0296] As a result of the experiment, when the antioxidant capacity of rose flower hot water extract and three types of rose-derived peptides with different types of enzymes was evaluated, it was confirmed that the rose-derived peptides produced by a plant-derived enzyme containing peptides corresponding to amino acid sequences 1 to 5 showed significantly superior antioxidant efficacy compared to general rose extract or rose-derived peptide compositions with different peptide sequences (Fig. 1).

[0297] When the antioxidant efficacy of rose-derived peptides was confirmed at different concentrations by a plant-derived enzyme containing peptides corresponding to amino acid sequences 1 to 5, which have excellent antioxidant efficacy, the effect was confirmed even at low concentrations of several ppm (w / v) (Fig. 2).

[0298] 2. Confirmation of the inhibitory effect of a rose-derived peptide composition on the secretion of neurotransmitters from nerve cells

[0299] If neurotransmitters secreted from nerve cells are not secreted, muscles cannot contract, and due to this mechanism, the formation of wrinkles is prevented or existing wrinkles are improved. Accordingly, in this experiment, the efficacy of inhibiting neurotransmitter secretion of rose-derived peptides produced by a plant-derived enzyme, rose-derived peptides produced by a fungal enzyme, and rose-derived peptides produced by a microbial enzyme, which are embodiments of the present disclosure, was conducted as follows.

[0300] 2-1. Comparison of neurotransmitter secretion inhibitory efficacy using Botulinum Toxin Type A as a positive control

[0301] Botulinum toxin Type A, which is well known for its neurotransmitter secretion inhibitory effect, was used as a positive control, and the effect of the rose-derived peptide of this example was compared with that of a synthetic peptide (Acetyl Hexapeptide-8).

[0302] Neuron cell line (SH-SY5Y, KCLB order no. 22266) was placed in a 6-well plate containing 10% FBS with DMEM / F12 at a 1.2 x 10 6 After seeding cells / well, they were cultured in a 37°C, 5% CO2 incubator for 5 days. After 5 days, the cells were treated with samples at different concentrations in DMEM / F12 containing 10% FBS for 3 days, then washed with 1 ml of potassium equilibrium salt solution (BSS) and re-cultured. The supernatant was collected by centrifugation, and the amount of noradrenalone produced was measured by absorbance at 450 nm using an ELISA KIT ELISA reader.

[0303] As a result of the experiment, when comparing the neurotransmitter secretion inhibitory efficacy with botulinum toxin Type A as a positive control, it was confirmed that the neurotransmitter secretion inhibitory efficacy of rose-derived peptides produced by plant-derived enzymes was superior to that of synthetic peptides (Fig. 3).

[0304] In addition, experimental results confirmed that the rose-derived peptide produced by a plant-derived enzyme containing a peptide having amino acid sequences 1 to 5 had significantly superior neurotransmitter secretion inhibitory efficacy compared to rose peptide compositions with different sequences (Fig. 4).

[0305] 3. Confirmation of the inhibitory effect of a rose-derived peptide composition on collagenase expression

[0306] Inhibiting the expression of MMP-1 (Matrix metalloproteinase-1; Collagenase-1), a collagen-degrading enzyme present in skin cells, can improve, prevent, or delay the decrease in collagen content within skin cells, thereby improving skin wrinkles and elasticity.

[0307] Accordingly, in order to confirm the efficacy of rose-derived peptides in improving skin wrinkles and elasticity by plant-derived enzymes, which is an embodiment of the present disclosure, cytotoxicity evaluation and an experiment on the efficacy of inhibiting the expression of MMP-1, a collagenase, were conducted as follows.

[0308] 3-1. Cytotoxicity Assessment

[0309] Normal human dermal fibroblasts were cultured in a 96-well plate at a concentration of 1.8 x 10⁶ in Dulbecco's Modified Eagle Medium (DMEM) containing penicillin, streptomycin, and growth factors. 4 After seeding at cells / well, the cells were cultured in a 37°C, 5% CO2 incubator for 24 hours to ensure proper adhesion to the plate. Human fibroblasts were cultured in serum-free DMEM medium, with the samples treated at different concentrations the following day. After 20 hours, the cells were treated with CCK8 solution to induce a reaction, and the absorbance was measured at 450 nm using an ELISA reader.

[0310] As a result of the experiment, it was confirmed that the rose-derived peptides produced by the plant-derived enzyme of the preparation example all showed a survival rate of 80% or more at a concentration of 100 μg / ml or less (Fig. 5).

[0311] 3-2. Evaluation of Collagen Degrading Enzyme (MMP-1) Inhibitory Efficacy

[0312] 1.8 x 10⁶ normal human keratinocytes in a 100 Φ dish 6Cells were seeded in cells / dish and cultured in KGM-Gold™ medium (Lonza, #192060) for 24 hours in a 37°C, 5% CO2 incubator. After washing once with phosphate-buffered saline, ultraviolet (UVB) radiation was applied at 25 mJ / cm². 2 After investigating with a force, KBM medium (Lonza, #192151) was added and cultured for 16 hours to obtain a culture solution.

[0313] Normal human dermal fibroblasts were cultured in a 96-well plate at a concentration of 1.8 x 10⁶ using DMEM medium containing penicillin, streptomycin, and growth factors. 4 After seeding at cells / well, the cells were cultured in a 37°C, 5% CO2 incubator for 24 hours to ensure proper adhesion to the plate. Human fibroblasts were starved for at least 7 hours using serum-free DMEM medium, and then cultured with the samples and UV-stimulated human keratinocyte culture medium as a stimulus. After 40 hours, the amount of MMP-1 produced in the cell culture medium was quantified using an ELISA kit (R&D system, DY901) and divided by cell viability to be compared with a negative control and a rose-derived peptide extract prepared with a general organic solvent.

[0314] As a result of the experiment, at concentrations of 2.5 ppm and 5 ppm, the levels decreased to approximately 0.65 times and 0.51 times, respectively, showing an MMP-1 expression inhibitory effect similar to that of the retinoic acid (RA; 2 μM) treatment group (Fig. 6).

[0315]

[0316] [Experimental Example 2: Composition for skin damage care or skin sagging improvement containing a novel peptide]

[0317] 1. Confirmation of cell viability induced by rose-derived peptides

[0318] The experimental method is as follows. Keratinocytes were placed in a 12-well plate at a density of 1.5 x 10 5 After inoculating with cells, the culture medium was switched to a keratinocyte culture medium without supplements after 1–2 days. Rose-derived peptides were added at various concentrations (ppm (µg / ml)) and cultured for 24 hours. 50 µl of Counting Kit-8 (CCK-8) solution was added to each well, incubated at 37°C for 30 minutes, and absorbance was measured at 450 nm using a Spectrostar Nano plate reader (BMG Labtech). Cell proliferation and toxicity effects were calculated as percentages based on the absorbance of the control group.

[0319] Experimental results confirmed that rose-derived peptides did not cause cytotoxicity at concentrations of 1 ppm, 3 ppm, and 10 ppm (Fig. 7).

[0320] 2. Confirmation of the effect of rose-derived peptides on restoring Col7A1 and Col17A1 expression

[0321] The experimental method is as follows. Keratinocytes were placed in a 12-well plate at a density of 1.5 x 10 5 After inoculating with cells, the culture medium was switched to a keratinocyte culture medium without supplements after 1 to 2 days. Fine dust (50 ppm (µg / ml)) and rose-derived peptides were treated at various concentrations (ppm (µg / ml)) and cultured for 24 hours. The specific particle sizes of the treated fine dust (SRM1648a, NIST) are as follows:

[0322] Mean particle diameter, d (0.5): 5.85 ㎛

[0323] Particle Diameter, d (0.1): 1.35 ㎛

[0324] Particle Diameter, d (0.9): 30.1 ㎛

[0325] * d (0.5): Refers to a particle size in which 50% of the volume of particles in the sample is less than or equal to this size.

[0326] RNA was extracted from cultured cells, and cDNA was synthesized from the extracted RNA. Subsequently, changes in the expression levels of Col7A1 and Col17A1 were observed using real-time qPCR on the 7500 FAST real-time PCR system (Applied Biosystems). The information on the Taqman probes used in the experiment is as follows: Col7a1 (Hs00164310_m1), Col17a1 (Hs00990036_m1), and RPL13A (Hs04194366_g1).

[0327] Experimental results showed that although the mRNA expression of collagen-type Col7A1 and Col17A1 was reduced by fine dust, when rose-derived peptides were simultaneously treated, the effect of the reduction in expression of each factor caused by fine dust was significantly mitigated (Figs. 8 and 9).

[0328]

[0329] [Experimental Example 3: Composition for anti-aging of skin containing a novel peptide]

[0330] 1. Comparative experiment of aging markers in young keratinocytes and aged keratinocytes

[0331] [Experimental Method]

[0332] Neonatal-derived keratinocytes (normal human epidermal keratinocytes, Lonza) were cultured in a 75 T flask using keratinocyte-specific medium (Epilife™, Gibco) until confluency of over 90% was achieved. Subsequently, cells were isolated by trypsin-EDTA treatment, and regenerated keratinocytes (replicative senescence: passage 6) were obtained by repeating subculture.

[0333] To compare the expression of aging-related genes in young cells (passage 3) and aged cells (passage 6), each cell was seeded into 6-well culture dishes at a density of 1.0 × 10⁴ cells / well and cultured at 37°C under 5% CO₂ conditions until approximately 80% confluency was reached. After removing the cell growth medium, 1 ml of Trizol™ (Invitrogen) was added to each well to isolate RNA according to the manufacturer's manual, and RNA concentration was quantified at 260 nm using a UV spectrophotometer (HEWLETT PACKARD). Subsequently, reverse transcription-polymerase chain reaction (RT-PCR) was performed using the extracted RNA.

[0334] Aging marker gene analysis was performed using the following TaqMan probe:

[0335] Col17a (Hs00990036_m1), Filaggrin (FLG, Hs00856927_g1), Kallikrein-related peptidase 5 (KLK5, Hs01548153_m1), Keratin 10 (KRT10, Hs00166289_m1), SRY-Box Transcription Factor 2 (SOX2, Hs04234836_s1), Claudin-1 (CLDN1, Hs00221623_m1), Cyclin-dependent kinase inhibitor 2A (p16, Gg07157676_m1), Matrix Metallopeptidase 2 (MMP-2, Hs01548727_m1).

[0336] The expression values ​​of each gene were corrected using the complementary reference gene RPL13A (Hs04194366_g1), and the analysis results are shown in Figure 10.

[0337] In addition, aged keratinocytes (passage 6) were treated with rose-derived peptide (10 ppm (w / w)) for 1 day, cultured under the same conditions (37℃, 5% CO₂), RNA was isolated using the same method as before, and RT-PCR was performed. The TaqMan probe and calibration method used for the analysis were identical, and the results are shown in Figure 11.

[0338] [Experimental Results]

[0339] In aged keratinocytes (p6), compared to young keratinocytes (p3), the expression of genes involved in skin structure and function, such as Col17a, FLG, KLK5, KRT10, SOX2, and CLDN, was generally reduced, while the expression of genes related to aging and extracellular matrix degradation, such as p16 and MMP-2, was increased (Fig. 10).

[0340] Meanwhile, when aged cells were treated with rose-derived peptides, the gene expression of Col17a, FLG, KLK5, KRT10, SOX2, and CLDN, which had decreased, was restored, while the expression of p16 and MMP-2, which had increased, showed a significant decreasing trend (Fig. 11).

[0341] These results suggest that rose-derived peptides are functional materials capable of inducing anti-aging at the cellular level by reversing the gene expression patterns of aged keratinocytes to the level of young cells.

[0342] 2. Preparation and Analysis of Aged Keratinocyte-Based Artificial Epidermis Treated with Rose-Derived Peptides

[0343] [Experimental Method]

[0344] Undifferentiated normal human epidermal keratinocytes (NHEKs) were supplied by Lonza (NHEK, 00192906) and cultured in 75 T flasks using low-calcium medium for NHEKs (Epilife™, MEPI500CA, Gibco) to maintain a confluency of over 90%. The cultured cells were isolated by trypsin-EDTA treatment, and senescence was induced at passage 9 through repeated seeding and subculture.

[0345] Aged NHEKs were treated with rose-derived peptide (10 ppm (w / w)) for 4 days for the experimental group and DMSO for the control group, respectively. After harvesting the cells with trypsin-EDTA, 300,000 cells from each group were seeded into artificial skin culture vessels (Corning Snapwell™, Transwell vessels with a polycarbonate membrane with 0.4 μm pores). Subsequently, submerged culture was performed for 24 hours using low-calcium NHEKs culture medium (Epilife™, 6 ml) to induce cell stabilization and proliferation, and 100% confluency was achieved within the membrane.

[0346] After 24 hours of culture, the medium was removed, and 6 ml of CnT medium (CnT-PR-3D, Cellntec) was added to perform in-liquid culture for another 24 hours to induce differentiation in the cells. Subsequently, the medium was completely removed, and only 1 ml of CnT medium was added to ensure contact only with the bottom membrane of the culture vessel, after which air-liquid interface culture was initiated. During this process, air was supplied from the top of the Transwell vessel, and cells not in direct contact with the medium were exposed to the air to induce differentiation.

[0347] The artificial epidermis formed 10 days after the start of culture was fixed with formalin and embedded in paraffin, then sectioned to a thickness of 3 μm, attached to a slide, and stained with Hematoxylin & Eosin. The stained samples were observed using an optical microscope, and the results are shown in Fig. 12.

[0348] [Experimental Results]

[0349] As shown in Fig. 12, in the artificial epidermis made from aged keratinocytes, a decrease in cell density due to apoptosis of basal layer cells, indistinct boundaries between cells in the spinous layer and granular layer, absence of keratohyalin granules in the granular layer, and the presence of numerous nuclei in the stratum corneum were observed. This indicates that normal differentiation of the epidermis did not occur and suggests that the skin barrier function was impaired.

[0350] On the other hand, in the artificial epidermis treated with rose-derived peptides, the number of basal layer cells per unit area was higher than in the control group, and clear boundaries were formed between cells within the spinous layer and granular layer. In addition, keratohyalin granules were observed normally within the granular layer, and normal keratinocyte structures with nuclei removed were confirmed within the stratum corneum.

[0351] These results indicate that rose-derived peptides improve the differentiation process of the epidermis damaged by aging and effectively contribute to the restoration of skin barrier function to young cells.

[0352] 3. Evaluation Experiment of Artificial Skin Using Keratinocytes by Age

[0353] [Experimental Method]

[0354] Artificial epidermis were prepared in the same manner as in Experimental Example 1 above in passage 2 using neonatal keratinocytes and adult keratinocytes from 45-year-olds, respectively. After culturing the artificial epidermis under air exposure conditions for 10 days, DMSO was applied to the control group and rose-derived peptide (10 ppm (w / w)) was applied to the experimental group, and each artificial epidermis was cultured for an additional 14 days.

[0355] Artificial epidermis cultured for a total of 24 days was fixed with formalin and embedded in paraffin, then sectioned to a thickness of 3 μm and attached to a slide. After staining with hematoxylin and eosin, the histological morphology was observed using a light microscope, and the results are shown in Fig. 13.

[0356] [Experimental Results]

[0357] As shown in Figure 13, the artificial epidermis produced using keratinocytes from 45-year-old adults did not show distinct morphological differences compared to the artificial epidermis produced using newborn-derived cells until 10 days of air exposure. However, during the subsequent 14 days of additional culture, aging-related tissue changes were observed in the adult cell-based artificial epidermis, such as mass death of basal layer cells, a decrease in the thickness of the spinous layer and granular layer, and a decrease in the density of keratohyalin granules within the granular layer.

[0358] On the other hand, when treated with rose-derived peptides under the same conditions, this histological regression was inhibited, and the stability of the epidermal structure tended to be maintained.

[0359] Meanwhile, the artificial epidermis using newborn-derived cells maintained an overall morphological structure similar to that of the 10-day mark even after an additional 14 days of culture, and no significant difference was observed between the rose-derived peptide treatment group and the control group. However, thickening of the natural stratum corneum was observed in both groups.

[0360] These results suggest that rose-derived peptides are a functional material effective in inhibiting age-related epidermal structural changes and functional decline induced in adult keratinocytes, restoring them to youthful cells, and maintaining healthy tissue structures within artificial epidermis.

[0361]

[0362] [Experimental Example 4: Skin Anti-glycation Composition Containing Novel Peptide]

[0363] 1. In vitro experiment

[0364] The experimental method of the present disclosure is as follows.

[0365] Before the test, the BSA powder reagent is dissolved in a DPBS solution to a concentration of 2.5% (w / v). The test samples—the rose-derived peptide obtained through the above preparation example and the Damask rose hot water extract (extracted from Damask rose flowers (Rosa damascenaflower) with 80°C water)—are prepared by dissolving them in water to a concentration 20X higher than the final test concentration. The glucose source is prepared as a 1M solution. Aminoguanidine (AG) was used as a positive control.

[0366] Using a 96-well plate (Black well, F-bottom, black, Greiner Bio-One product Cat #655090), add 100 µL of 2.5% BSA, 100 µL of 1M Glucose, and 10 µL of the 20X test or control sample, and mix well. Incubate in a 50℃ incubator for 7 days. Measure using a spectrometer under excitation 360 nm / emission 440 nm wavelength conditions. After obtaining the fluorescence intensity for each well, plot the Relative amounts of AGEs (% of induction by glucose) on the vertical axis. The difference in increased fluorescence intensity in the glucose-treated group compared to the glucose-untreated group (Control) was set to 100%, and the decrease in fluorescence intensity for each sample was calculated as a percentage and plotted on a graph.

[0367] As a result of the experiment, it was confirmed that the fluorescence value of AGEs reacted with glucose was reduced significantly by rose-derived peptide when converted to 100%.

[0368] In addition, when compared with Damask rose hot water extract under the same experimental conditions including treatment concentration, it was confirmed that the rose-derived peptide had significantly superior AGEs inhibitory ability compared to the rose hot water extract in comparisons between all groups at concentrations of 25 ppm, 50 ppm, and 100 ppm (w / v), respectively (Fig. 14).

[0369] 2. Cell experiment

[0370] The experimental method of the present disclosure is as follows.

[0371] Fibroblasts (HDFn) were cultured in DMEM (Lonza, #12-604F) medium containing 10% FBS (Gibco, #16000-044) and P / S (Lonza, #17-602E) at 37°C in a 5% CO2 incubator. After cell counting, the cells were at a final concentration of 5.0 x 10⁶ 5 Adjust to cells / mL. Add the three ingredients listed in Table 3 below to a 50mL tube in order and mix with an electric pipette to prevent air bubbles from forming. At this time, the collagen solution (Step 1) and NaOH solution (Step 3) should be mixed while kept cold and not pre-warmed.

[0372]

[0373] Order x1 x 11 Type 1 Collagen Solution 100 μL 2 Cell Culture Medium (w / cells) 200 μL 3 1N NaOH 7.5 μL Total 307.5 μL

[0374] Mix 300ul per well for the required number of wells.

[0375] 300 μL was added to each well of a 48-well plate and solidified in a 37°C, 5% CO2 incubator for 90 minutes. As the gel solidified, the outer surface of the gel attached to the well plate walls was scraped off with a yellow tip to separate it (this was done to keep the gel floating on the culture medium to prevent cells from escaping). Thirty minutes prior, a fresh glucose solution (30 mM in culture media) was prepared and pre-warmed at 37°C (culture media for the untreated group was also pre-warmed). AG (aminoguanidine, MW=123.1) was prepared as a positive control. 300 μL of culture medium mixed with the positive control and rose-derived peptides at various concentrations (ppm (w / v)) was added to each well.

[0376] Incubate in a 37°C, 5% CO2 incubator for 7 days. After 7 days, remove the culture media and fix with 4% formaldehyde for 20 minutes.

[0377] After washing with PBS, the samples were transferred to a 96-well black plate (F-bottom, black, Greiner Bio-One Cat #655090) and measured using a spectrometer under conditions of excitation 360 nm / emission 440 nm. Fluorescence intensity values ​​were obtained for each well. Average values ​​were calculated for each group, and graphs were produced (Fig. 15).

[0378] The results of this experiment were conducted with n=8 per group, and each experimental result was indicated by a filled square, while the average value for each group was indicated by a straight bar (excluding minimum & maximum values, n=6).

[0379] As a result of the experiment, the relative fluorescence intensity in the group treated with glucose (30 mM) was 10.7 ± 0.1 (×1000), which was an increase of about 32.1% compared to 8.1 ± 1.0 (×1000) in the control group, confirming that intracellular glycosylation reactions were induced by high concentrations of glucose.

[0380] Meanwhile, in the positive control group treated with glucose and aminoguanidine (20 mM), the fluorescence intensity recovered to the control level at 8.1 ± 1.0 (×1000), which suggests that the production of AGE (Advanced Glycation End-products) was inhibited.

[0381] When glucose and rose-derived peptides were treated together, distinct inhibitory effects were observed depending on the concentration. Specifically, the fluorescence intensities of the 25 ppm, 50 ppm, and 100 ppm treatment groups were 7.3 ± 0.6, 7.2 ± 0.8, and 6.8 ± 0.4 (×1000), respectively, and the relative fluorescence intensities compared to the untreated group decreased by 89.5%, 89.1%, and 83.4%, respectively. The glycation inhibition rates calculated from this reached 42.6%, 42.9%, and 48.7%, respectively.

[0382] These results demonstrate that the rose-derived peptide of the present disclosure can effectively inhibit AGE formation in fibroblasts under glucose-induced conditions.

[0383]

[0384] [Experimental Example 5: Composition for preventing hair loss or promoting hair growth containing a novel peptide]

[0385] 1. Experiment to Evaluate Efficacy of Hair Papillary Cell Proliferation

[0386] 1) Isolation and culture of dermal papilla cells

[0387] After performing a hair follicle transplant on a 26-year-old female with alopecia, occipital scalp tissue was obtained. Dermal papilla cells were isolated from the obtained occipital scalp tissue using a microscope and cultured for 14 days in 35 mm culture dishes (BD Biosciences, San Diego, CA, USA) coated with collagen type I, with the medium changed every 3 days. At this time, Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD) (5% CO2, 37℃) containing 10 μg / ml streptomycin (Gibco, NY, USA), 100 U / ml penicillin (Gibco, NY, USA), and 20% heat-inactivated fetal bovine serum (FBS, Lonza, Walkersville, MD) was used as the culture medium. When the cells reached 80% confluence, the cells were collected using 0.25% trypsin / 10mM EDTA (Gibco, NY, USA), and the collected cells were cultured in DMEM medium supplemented with 10% FBS.

[0388] 2) Culture for dermal papilla cell proliferation

[0389] Dermal papilla cells were seeded at a density of 2,000 per well in 96-well plates (Nunc, Wiesbaden, Germany) and cultured for 24 hours (5% CO2, 37°C). Then, each material (rose flower hot water extract, rose-derived peptide, Acetyl Dipeptide-1 Cetyl ester) was applied (ppm (w / v)) and cultured for an additional 96 hours. Meanwhile, for comparison, the control group was cultured without any treatment.

[0390] The above rose flower hot water extract was obtained by extracting Damask rose (Rosa damascena flower) with water at 80°C, and Acetyl Dipeptide-1 Cetyl ester was prepared and used as calmosensine from Croda.

[0391] 3) Measurement of cell proliferation

[0392] MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma, St Louis, MO) solution (70 µg / well) was added to each well of a 96-well plate containing cultured cells and incubated for 3 hours. Then, 100 µl of DMSO (dimethyl sulfoxide; Sigma, St Louis, MO) was added per well and the absorbance was measured at 570 nm (ELISA Reader).

[0393] 4) Analysis of experimental results

[0394] The experimental results were calculated by setting the control group without added active ingredients to 100 and calculating the relative values, and the respective results are shown in Fig. 16.

[0395] Specifically, when evaluating the dermal papilla cell proliferation ability of rose flower hot water extract, rose-derived peptide, or Acetyl Dipeptide-1 Cetyl ester, a significant increase in dermal papilla cell proliferation was observed in the groups treated with rose-derived peptide or Acetyl Dipeptide-1 Cetyl ester.

[0396] 2. Experiment to evaluate the efficacy of inhibiting external root sheath cell apoptosis

[0397] 1) Cell preparation

[0398] Outer root sheath (ORS) cells were isolated from hair follicles, and the culture medium consisted of Epilife media supplemented with 1% antibiotics and 1% EDGS; cells were cultured in collagen type 1 coated dishes / flasks (refer to NCS-ETP-052 for details). For ORS cells, 2 x 10⁶ 4Cells were seeded into collagen type 1 coated 96-well plates at a rate of cells / well. The cell count could be adjusted according to the treatment time, and the principle was to maintain a cell density of approximately 80–90% of the control level on the day of the assay. Cells were cultured at 37°C under 5% CO2 conditions.

[0399] 2) Treatment of materials

[0400] After culturing the cells for 24 hours, the medium was removed and the cells were washed with medium free of EDGS. Samples for efficacy evaluation were then pretreated at various concentrations (ppm (w / v)). Following the pretreatment, the samples at each concentration were added to 33 μM H2O2, 33 ng / ml DKK-1, and 33 ng / ml TGFβ2 for further incubation. The CCK8 reagent was prepared by diluting the corresponding cell culture medium to a concentration of 5–10%. The medium was removed and washed with DPBS. The prepared CCK8 solution was added to the cells, and they were incubated for 2 hours in a 37°C CO2 incubator. Absorbance at 450 nm was measured using a Microplate Reader (SpectraMax 190).

[0401] 3) Data processing method

[0402] The method for processing the data obtained from the above sample is as follows:

[0403] It is based on the absorbance of the control group that was not treated with the sample.

[0404] The number of cells in the hair loss-inducing group and the sample-treated group is converted into a percentage value compared to the control group.

[0405] Conversion Formula (% of Control) = (450nm OD of Sample Group / 450nm OD of Control Group) X 100

[0406] To determine the cell death inhibition rate, the difference between the % number of cells in the hair loss-inducing group and the % number of cells in the sample-treated group is divided by the % number of cells in the control group and the hair loss-inducing group, and then multiplied by 100 to indicate the result.

[0407] [Mathematical Formula 1]

[0408] Cell death inhibition rate (% of catagen-induced group)

[0409] =(Sample treatment group % - Hair loss inducing group %) / (Control group % - Hair loss inducing group %) X 100.

[0410] When rose-derived peptides and Acetyl Dipeptide-1 Cetyl ester are used together, the expected value (inhibition rate of apoptosis in outer root sheath cells) was calculated using the Colby equation.

[0411] The calculation process and results are shown below. Here, “synergistic effect” refers to the definition in [Colby, SR “Calculating synergistic and antagonistic responses of herbicide combinations.” Weeds 15.1 (1967): 20-22].

[0412]

[0413] [Colby formula when two active ingredients are used in combination]

[0414] Colby formula: Expected value = A + B - (A*B / 100)

[0415] A: Observed efficacy of active ingredient A at the same concentration as used in the mixture

[0416] B: Observed efficacy of active ingredient B at the same concentration as used in the mixture

[0417] 4) Analysis of experimental results

[0418] When hair loss-inducing cells (H2O2+DKK-1+TGFβ2) were treated, a significant increase in apoptosis was observed, and when treated with a combination of rose-derived peptide and Acetyl Dipeptide-1 Cetyl ester, a statistically significant level of apoptosis inhibition efficacy was confirmed (Fig. 17).

[0419] In addition, to calculate the expected inhibition rate of apoptosis (expected value) of outer root sheath cells when rose-derived peptides and Acetyl Dipeptide-1 Cetyl ester are used together, the inhibition rate of apoptosis of the hair loss-inducing group and the experimental group treated only with rose-derived peptides was substituted into A of the above Colby formula, and the inhibition rate of apoptosis of the hair loss-inducing group and the experimental group treated with Acetyl Dipeptide-1 Cetyl ester was substituted into B. After calculating the expected value according to the Colby formula, the value is shown in Table 3 below.

[0420] In addition, the degree of the synergistic effect was calculated and shown together in Table 4 below. The values ​​in Table 3 were rounded to the second decimal place and displayed only up to the first decimal place.

[0421]

[0422] Treatment Sample Actual Apoptosis Inhibition Rate (%) Expected Apoptosis Inhibition Rate (%) Synergistic Effect (%) Rose-derived peptide 10 ppm + Acetyl Dipeptide-1 Cetyl ester 1 ppm 98.38 6.412 Rose-derived peptide 10 ppm + Panthenol 10 ppm 60.78 8.9 No effect Rose-derived peptide 10 ppm + Biotin 10 ppm 63.88 9.8 No effect

[0423] Therefore, as shown in Table 4 above, when rose-derived peptide and Acetyl Dipeptide-1 Cetyl ester were used together, it was confirmed that the actual cell death inhibition rate of the combination of the two active ingredients was increased by about 12% compared to the combination of 10 ppm and 1 ppm of the two substances, respectively, compared to the predicted expected value.

[0424] In other words, it was found that the combination of rose-derived peptides and Acetyl Dipeptide-1 Cetyl ester exhibited a significant synergistic effect in inhibiting the death of outer root sheath cells in hair follicles. In contrast, it was confirmed that there was no synergistic effect when panthenol and biotin, which are known to have anti-hair loss and hair growth effects, were treated together.

[0425]

[0426] [Experimental Example 6: Composition for improving skin barrier function containing a novel peptide]

[0427] 1. Experiment on the Efficacy of Improving Inhibition of Keratinocyte Endogenous Differentiation Marker Expression Caused by Stress Hormone (Cortisol) - Subject to Keratinocytes

[0428] Keratinocytes (NHEK-neo, Lonza) were 1.5 x 10⁶ in a 12-well plate 5 After inoculating with cells, the culture medium was replaced with a supplement-free keratinocyte culture medium after 1–2 days. Cortisol (10 μM) or blue light (450 nm, 120 J / cm²) were used as skin barrier damage agents, respectively. 2 ) was selected, and cells were treated with cortisol or blue light and rose-derived peptides at various concentrations (1–10 ppm (w / v)) and cultured for 3 days (control: untreated control, NT: cortisol-treated control). RNA was extracted from the cells, cDNA was synthesized from the extracted RNA, and changes in gene expression levels were observed using real-time qPCR.

[0429] The experimental results are as follows.

[0430] 1) It was confirmed that the decrease in differentiation markers (KRT1, KRT10, FLG, LOR) in keratinocytes caused by the stress hormone (cortisol) was improved by treatment with rose-derived peptides (Fig. 18).

[0431] 2) It was confirmed that the reduction of differentiation markers (KRT1, KRT10, LOR, FLG), moisturization markers (CASP14, FLG), and intercellular binding markers (CLDN, TJP1) in keratinocytes caused by blue light was improved by treatment with rose-derived peptides (Fig. 19).

[0432] 2. Comparative experiment on the efficacy of improving inhibition of keratinocyte endogenization marker expression induced by the stress hormone (cortisol) - Keratinocytes

[0433] Keratinocytes (Human Epidermal Keratinocytes, neonatal (HEKn), Thermo Fisher Scientific) were 1.5 x 10⁶ in a 12-well plate 5 After inoculating with cells, the culture medium was replaced with a keratinocyte culture medium without supplements after 1 to 2 days. Cortisol (10 μM) was selected as the skin barrier damage agent, and cells were treated with cortisol and rose-derived peptide 5 ppm (w / v) and cortisol and rose extract (extracted from Damask rose (Rosa damascenaflower) with 80°C water; rose hot water extract) 5 ppm (w / v) and cultured for 3 days (control: untreated control, NT: cortisol-treated control). RNA was extracted from the cells, cDNA was synthesized from the extracted RNA, and changes in gene expression levels were observed using real-time qPCR.

[0434] Experimental results confirmed that the reduction of differentiation markers (KRT1, FLG) in keratinocytes caused by the stress hormone (cortisol) was significantly increased by treatment with rose-derived peptides compared to rose extract (Figs. 20 and 21).

[0435] 3. Experiment on the Efficacy of Improving Inhibition of Keratinocyte Keratinization Marker Expression by Injuring Agents - Subject to Artificial Skin

[0436] Keratinocytes (Human Epidermal Keratinocytes, neonatal (HEKn), Thermo Fisher Scientific) were placed in a Snapwell plate at a volume of 2.0 x 10⁶ 5 After laying cells, an epidermal layer was formed by performing air exposure culture for 2 weeks. After the formation of the epidermal layer, under culture medium conditions where hydrocortisone (cortisol) was removed, cortisol (10 μM) alone or cortisol and rose-derived peptide (10 ppm (w / v)) were added to the medium, and tissue changes were observed through histological observation after culturing for 1 week with the culture medium changed every other day.

[0437] Experimental results confirmed that the reduction of keratinocyte differentiation markers (KRT10, FLG) in artificial skin caused by the stress hormone (cortisol) was improved by treatment with rose-derived peptides (Fig. 22).

[0438] [Amino acid sequence of rose-derived peptides]

[0439] 1. SSANGPLGGGAGM (Sequence No. 1)

[0440] 2. RGMSPGGGGGGGL (Sequence No. 2)

[0441] 3. STGANLAAASNP (Sequence No. 3)

[0442] 4. STENLGGGGVAN (Sequence No. 4)

[0443] 5. TSNGALGGVSPN (Sequence No. 5)

Claims

1. A peptide comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5.

2. In Paragraph 1, (a) The above peptide is a rose-derived peptide and / or; (b) The above peptide is derived from a rose water extract and / or; (c) The above peptide is composed of one or more amino acid sequences selected from the group consisting of SEQ ID NOs 1 to 5 and / or; (d) The above peptide is a peptide obtained by adding a plant-derived enzyme to a rose-derived protein and / or; (e) The above peptide is a peptide obtained by adding cysteine ​​protease to a rose-derived protein and / or, (f) The above peptide is a peptide obtained by adding bromelain to a rose-derived protein.

3. A rose-derived extract containing the peptide according to paragraph 1.

4. A skin-improving composition comprising a rose-derived peptide, and The above skin improvement is one or more of the following: improvement of skin aging, antioxidant, care for skin damage, improvement of skin sagging, anti-aging of the skin, anti-glycation, improvement of skin tone, prevention of hair loss or promotion of hair growth, strengthening of hair roots, promotion of eyelash growth, or improvement of skin barrier function damaged by exosomes.

5. In Paragraph 4, (a) The above skin aging improvement is Improving skin wrinkles, skin elasticity, or skin keratinization The above-mentioned improvement of skin aging involves inhibiting the secretion of neurotransmitters, and / or The above-mentioned improvement of skin aging is to inhibit the expression of collagen-degrading enzymes and / or; (b) The above composition is applied to dermal fibroblasts and / or keratinocytes and / or; (c) The above improvement of skin damage or skin sagging restores damage to the dermoepidermal junction, and / or The above-mentioned improvement of skin damage or skin sagging increases the expression of collagen within the skin and / or; (d) A composition in which the skin damage is skin damage caused by fine dust.

6. In Paragraph 5, The above neuronal substance is noradrenaline, and / or The above collagen-degrading enzyme is MMP-1 (Matrix metalloproteinase-1; Collagenase-1), and / or The above collagen is a composition in which the collagen is collagen type Col7A1 or Col17A1.

7. In Paragraph 4, (a) The above anti-aging comprises one or more selected from the group consisting of increased skin moisturizing ability, strengthening of the epidermal barrier, improvement of cell division ability, normalization of epidermal differentiation, increased skin regeneration ability, improvement of keratin shedding regulation, strengthening of intercellular adhesion, and inhibition of substrate-degrading enzyme activity; (b) The above anti-aging improves one or more phenomena selected from the group consisting of a decrease in basal layer cell density of the skin induced by aging, indistinctness of intercellular boundaries, absence of keratohyalin granules and persistence of nuclei within the stratum corneum; and / or; (c) The above anti-aging increases the mRNA expression of one or more selected from the group consisting of Col17a (Collagen type XVII alpha 1 chain), FLG (Filaggrin), KLK5 (Kallikrein-related peptidase 5), KRT10 (Keratin 10), SOX2 (SRY-Box Transcription Factor 2) and CLDN1 (Claudin-1), and / or A composition that reduces mRNA expression levels of p16 (Cyclin-dependent kinase inhibitor 2A) and / or MMP-2 (Matrix Metallopeptidase 2).

8. In Paragraph 4, (a) The above anti-glycation or skin tone improvement inhibits the formation of Advanced Glycation End products and / or; (b) The above skin tone improvement is an improvement in the yellow tone or yellowing of the skin and / or; (c) The above skin improvement is anti-glycation or skin tone improvement, and A composition in which the above rose-derived peptide is treated to cells at a concentration of 0.25 to 10,000 ppm (w / v).

9. In Paragraph 4, The above skin improvement is prevention of hair loss or promotion of hair growth; strengthening of hair roots; or promotion of eyelash growth, and The above composition further comprises acetyl dipeptide-1 cetyl ester.

10. In Paragraph 9, (a) The above composition comprises the rose-derived peptide and the acetyldipeptide-1-cetyl ester in a weight ratio of 1 to 100:1 and / or; (b) The composition comprises 0.00001 to 0.1 weight% of the rose-derived peptide, and / or Including 0.000001 to 0.01 weight% of the above acetyl dipeptide-1-cetyl ester; and / or (c) The above rose-derived peptide is treated to cells at a concentration of 0.1 to 1000 ppm (w / v), and / or The above acetyl dipeptide-1-cetyl ester is treated to cells at a concentration of 0.01 to 100 ppm (w / v) and / or; (d) A composition that prevents hair loss or promotes hair growth; strengthens hair roots; or promotes eyelash growth, which proliferates hair papilla cells and inhibits the death of outer root sheath cells.

11. In Paragraph 4, (a) The exosome is mental stress and / or blue light and / or; (b) Improvement of damaged skin barrier function by the above exosome is one or more selected from the group consisting of promotion of keratinocyte differentiation, promotion of intercellular binding of keratinocytes, and improvement of skin hydration; or; (c) Improvement of impaired skin barrier function by the above exosome promotes the expression of one or more mRNAs selected from the group consisting of KRT1 (Keratin 1), KRT10 (Keratin 10), FLG (Filaggrin), LOR (Loricrin), CASP14 (Caspase 14), CLDN1 (Claudin 1) and TJP1 (Tight Junction Protein 1); (d) The above composition is applied to the epidermal layer of the skin and / or; (e) The skin improvement is the improvement of damaged skin barrier function by an exosome, and the rose-derived peptide is treated to cells at a concentration of 0.1 to 100 ppm (w / v), a composition.

12. In Paragraph 11, The above mental stress is stress caused by glucocorticoid hormones and / or, A composition in which the wavelength of the blue light is 380 to 500 nm.

13. In Paragraph 12, A composition in which the above-mentioned glucocorticoid hormone is one or more selected from cortisol, cortisone, and corticosterone.

14. In Paragraph 4, (a) The above rose-derived peptide is a rose flower-derived peptide and / or; (b) The rose-derived peptide is derived from a rose water extract and / or; (c) The rose-derived peptide comprises one or more amino acid sequences selected from the group consisting of SEQ ID NOs. 1 to 5 and / or; (d) The rose-derived peptide is a peptide obtained by adding a plant-derived enzyme to a rose-derived protein and / or; (e) A composition in which the rose-derived peptide is a peptide obtained by adding cysteine ​​protease to a rose-derived protein.

15. A method for preparing a peptide according to claim 1 or 2, a rose-derived extract according to claim 3, or a composition according to any one of claims 4 to 14, wherein Step of preparing rose (Rosa damascena) extract; A step of precipitating rose-derived protein from the above rose extract; A step of hydrolyzing the above rose-derived protein by treating it with a proteolytic enzyme; and A manufacturing method comprising the step of inactivating the above-mentioned proteolytic enzyme.

16. In Paragraph 15, The preparation of the above rose (Rosa damascena) extract is carried out by hot water extraction of rose flowers, or The precipitation of the above rose-derived protein is performed by adjusting the pH of the rose extract to 8 or higher to induce elution, and then adjusting the pH to 5 or lower, or A method for manufacturing, further comprising the step of neutralizing the protein by adjusting the pH of the rose extract to 6 to 8 after the step of precipitating the protein and before the step of hydrolyzing the protein.

17. In claim 1 or 2, the peptide is a peptide prepared by the method of claim 15.

18. In paragraph 3, the peptide is a rose-derived extract prepared by the method of paragraph 15.

19. In any one of claims 4 to 14, the composition is prepared by a method comprising the following: Step of preparing rose (Rosa damascena) extract; A step of precipitating rose-derived protein from the above rose extract; A step of hydrolyzing the above rose-derived protein by treating it with a proteolytic enzyme; and Step of inactivating the above-mentioned protein-degrading enzyme.

Images